Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  25-Jul-2018A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate
 the Interchangeability of V114 and Prevnar 13™ with Respect to 
Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-
DIRECTION)
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Title Page
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME 
CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind Study  to Evaluate the 
Interchangeabilit y of V114 and Prevnar 13™ with R espect to Safet y, Tolerability, and 
Immunogenicity in Healthy Infants (PNEU -DIRECTI ON)
Protocol Number: 027-00
Compound Number: V114
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT14115
2018 -001151 -12
Approval Date: 25-Jul-2018 
  04ZGY9 
  05PZF8

PRODUCT: V114 2
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study File 
Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol and 
to abide by  all provisions of this protocol.
Typed Name:
Title:Date 
  04ZGY9 
  05PZF8

PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table of Contents
1 PROTOCOL SUMMARY ............................................................................................ 10
1.1 Synopsis ................................................................................................................. 10
1.2 Schema .................................................................................................................. 15
1.3 Schedule of Activities (SoA) ................................................................................ 16
2 INTRODUCTION .......................................................................................................... 26
2.1 Study Rationale .................................................................................................... 26
2.2 Background .......................................................................................................... 26
2.2.1 V114 and Pneumococcal Disease ................................................................ 26
2.2.2 Preclinical and Clinical Studies ................................................................... 27
2.2.3 Information on Other Study -related Therap y.............................................. 28
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESIS, OBJECTIV ES, AND ENDPO INTS ................................................. 28
4 STUDY DESIGN ............................................................................................................ 31
4.1 Overall Design ...................................................................................................... 31
4.2 Scientific Rationale for Study Design ................................................................ .32
4.2.1 Rationale for Endpoints ............................................................................... 33
4.2.1.1 Immunogenicit y Endpoints ................................................................ 33
4.2.1.2 Safety  Endpoints ................................................................................ 34
4.2.1.3 Future Biomedical Research .............................................................. 34
4.2.2 Rationale for the Use of Comparator ........................................................... 34
4.3 Justification for Dose ........................................................................................... 35
4.4 Beginning and End of Study Definition ............................................................. 35
4.4.1 Clinical Criteria for Early Study Termination ............................................. 35
5 STUDY POPULATION ................................................................................................ 35
5.1 Inclusion Criteria ................................................................................................ .36
5.2 Exclusion Criteria ................................................................................................ 36
5.3 Lifestyle Considerations ...................................................................................... 38
5.4 Screen Failures ..................................................................................................... 38
5.5 Participant Replacement Strategy ...................................................................... 38
6 STUDY INTERVENTION ............................................................................................ 38
6.1 Study Intervention(s) Administered ................................................................... 40
6.2 Preparation/Handling/Storage/Accountability ................................................. 41
6.2.1 Dose Preparation .......................................................................................... 41
6.2.2 Handling, Storage, and Accountability ........................................................ 41
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 42
6.3.1 Intervention Assignment.............................................................................. 42 
  04ZGY9 
  05PZF8

PRODUCT: V114 4
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
6.3.2 Stratification ................................................................................................ .42
6.3.3 Blinding ........................................................................................................ 42
6.4 Study Intervention Compliance .......................................................................... 43
6.5 Concomitant Therapy .......................................................................................... 43
6.5.1 Rescue Medications and Supportive Care ................................................... 45
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 45
6.7 Intervention After the End of the Study ............................................................ 45
6.8 Clinical Supplies Disclosure ................................................................................ 45
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 46
7.1 Discontinuation of Study Intervention ............................................................... 46
7.2 Participant Withdrawal From the Study ........................................................... 47
7.3 Lost to Follow -up................................................................................................ .47
8 STUDY ASSESSMENTS AN D PROCEDURES ........................................................ 47
8.1 Administrative and General Procedures ........................................................... 48
8.1.1 Informed Consent ......................................................................................... 48
8.1.1.1 General Informed Consent ................................................................ .48
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 49
8.1.2 Inclusion/Exclusion Criteria ........................................................................ 49
8.1.3 Participant Identification Card ..................................................................... 49
8.1.4 Medical History ........................................................................................... 50
8.1.5 Prior and Concomitant Medications Review ............................................... 50
8.1.5.1 Prior Medications ............................................................................... 50
8.1.5.2 Concomitant Medications .................................................................. 50
8.1.6 Assignment of Screening Number ............................................................... 50
8.1.7 Assignment of Treatment/Randomization Number ..................................... 51
8.1.8 Study  Intervention Administration .............................................................. 51
8.1.8.1 Timing of Dose Admini stration ......................................................... 52
8.1.9 Electronic Vaccination Report Card ............................................................ 52
8.1.10 Telephone Contact Guide for Day  15 Post Each Dose ................................ 53
8.1.11 Telephone Contact Questionnair e................................................................ 53
8.1.12 Discontinuation and Withdrawal ................................................................ .53
8.1.12.1 Withdrawal Fro m Future Biomedical Research ................................ 53
8.1.13 Participant Blinding/Unblinding .................................................................. 54
8.1.14 Calibration of Equipment ............................................................................. 54
8.2 Immunogenicity Assessments ............................................................................. 55
8.2.1 Pneumococcal Electrochemiluminescence (PnECL) ................................... 55 
  04ZGY9 
  05PZF8

PRODUCT: V114 5
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.2.2 Hepatitis B Enhanced Chemiluminescence (ECi) Assay ............................. 56
8.2.3 Rotavirus Serum IgA Enzy me-Linked Immunosorbent Assay  (EIA) ......... 56
8.3 Safety Assessments ............................................................................................... 57
8.3.1 Physical Examinations ................................................................................. 57
8.3.2 Body Temperature Measurement ................................................................ .57
8.3.3 Safety  Assessment and Use of the eVRC .................................................... 58
8.3.4 Clinical L aboratory  Assessments ................................................................ .58
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 58
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other Reportable 
Safety  Event Information ............................................................................. 59
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......60
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...61
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 61
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 61
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualify ingas 
AEs or SAEs ................................................................................................ 61
8.4.7 Events of Clinical I nterest (ECI s)................................................................ 61
8.5 Treatment of Overdose ........................................................................................ 61
8.6 Pharmacokinetics................................................................................................ .62
8.7 Pharmacodynamics .............................................................................................. 62
8.8 Future Biomedical Research Sample Collection ............................................... 62
8.9 Planned G enetic Analysis Sample Collection .................................................... 62
8.10 Biomarkers ........................................................................................................... 62
8.11 Medical Resource Utilization and Health Economics ....................................... 62
8.12 Visit Requirements ............................................................................................... 62
8.12.1 Screening ...................................................................................................... 63
8.12.2 Treatment Period/Vaccination Visits ........................................................... 63
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 63
9 STATISTICAL ANALYSIS PLAN ............................................................................. 63
9.1 Statistical Analysis Plan Summary..................................................................... 63
9.2 Responsibility for Analyses/In -house Blinding ................................................. 66
9.3 Hypotheses/Estimation ........................................................................................ 66
9.4 Analysis Endpoints ............................................................................................... 66
9.4.1 Immunogenicit y Endpoints .......................................................................... 66
9.4.2 Safety  Endpoints .......................................................................................... 67
9.5 Analysis Populations ............................................................................................ 68
9.5.1 Immunogenicit y Analysis Populations ........................................................ 68 
  04ZGY9 
  05PZF8

PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
9.5.2 Safety Anal ysis Populations ........................................................................ 69
9.6 Statistical Methods ............................................................................................... 69
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 69
9.6.2 Statistical Methods for Safety Anal yses...................................................... 72
9.6.3 Demographic and Baseline Characteristics ................................................. 75
9.7 Interim Analyses .................................................................................................. 76
9.8 Multiplicity ........................................................................................................... 76
9.9 Sample Size and Power Calculations ................................................................ .77
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 77
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 78
9.10 Subgroup Analyses ............................................................................................... 79
9.11 Compliance (Medication Adherence) ................................................................ .79
9.12 Extent of Exposure ............................................................................................... 79
10 SUPPORTING DOCUMENTA TION A ND OPERATIONAL 
CONSIDERATIONS ..................................................................................................... 80
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ 80
10.1.1 Code of Conduct for Clinical Trials ............................................................. 80
10.1.2 Financial Disclosure ..................................................................................... 82
10.1.3 Data Protection ............................................................................................. 82
10.1.3.1 Confidentiality  of Data ...................................................................... 83
10.1.3.2 Confidentiality  of Participant Records ............................................... 83
10.1.3.3 Confidentiality  of IRB/IEC I nformati on............................................ 83
10.1.4 Committees Structure ................................................................................... 83
10.1.4.1 Scientific Advisory  Committee .......................................................... 83
10.1.4.2 Executive Oversight Committee ........................................................ 83
10.1.4.3 External Data Monitoring Committee ............................................... 84
10.1.5 Publication Policy ........................................................................................ 84
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...84
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 85
10.1.8 Data Qualit y Assurance ............................................................................... 85
10.1.9 Source Documents ....................................................................................... 86
10.1.10 Study  and Site Closure ................................................................................. 86
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 87
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 88
10.3.1 Definition of AE .......................................................................................... 88
10.3.2 Definition of SAE ........................................................................................ 89
10.3.3 Additional Events Reported ......................................................................... 90 
  04ZGY9 
  05PZF8

PRODUCT: V114 7
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.3.4 Recording AE and SAE ............................................................................... 90
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the Sponsor 93
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................... 95
10.5 Appendix 5: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 96
10.6 Appendix 6: Country -specific Requirements .................................................. 101
10.7 Appendix 7: Abbreviations ............................................................................... 102
11 REFERENCES............................................................................................................. 104 
  04ZGY9 
  05PZF8

PRODUCT: V114 8
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
LIST OF TABLES
Table 1 V114/Prevnar 13™ Dosing Schedule .............................................................. 32
Table 2 Study  Interventions .......................................................................................... 40
Table 3 Concomitant Vaccine Schedule ....................................................................... 44
Table 4 Recommended Injection -Site L ocation for Study  Interventions ..................... 45
Table 5 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events ....................................................................... 60
Table 6 Analy sis Strategy  for Immunogenicit y Variables ............................................ 72
Table 7 Analy sis Strategy for Safety  Parameters .......................................................... 75
Table 8 95% CI s for Vary ing Hypothetical IgG GMC Ratios and Vary ing 
Standard Deviations with 135 Evaluable Participants in Each 
Vaccination Group ........................................................................................... 77
Table 9 Differences in Incidence of Adverse Event Rates between the 2 
Vaccination Groups That Can be Detected With an ~80% Probability  
(Assuming 2- sided 5% alpha lev el with 180 Participants in each 
Group) .............................................................................................................. 79 
  04ZGY9 
  05PZF8

PRODUCT: V114 9
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
LIST OF FIGURES
Figure 1 V114 -027 Study  Design ................................................................................... 15 
  04ZGY9 
  05PZF8

PRODUCT: V114 10
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind Study  to Evaluate the 
Interchangeability  of V114 and Prevnar 13™ with Respect to Safet y, Toler ability , and 
Immunogenicity in Healthy Infants (PNEU -DIRECTI ON)
Short Title: Safet y and Immunogenicit y of the Interchangeability between V114 and Prevnar 
13™ in Healthy  Infants
Acronym: PNEUmococcal Conjugate Vaccine Trials : V114 -027(PNEU -DIRECTION )
Hypotheses, Objectives ,and Endpoints :
The following h ypotheses, objectives and endpoints will be evaluated in healthy infants 
administered V114 or Prevnar 13™ in 1 of 5 intervention groups:
Group 1 : Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2 : Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3 : Prevnar 13™ →Prevnar 13™ → V114 →V114
Group 4 : Prevnar 13™ →V114 →V114 →V114
Group 5 : V114 →V114 →V114 →V114
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of complete V114 (Group 5) and 
mixed Prevnar 13™/V114 dosing schedules 
(Groups 2, 3, and 4) compared with a complete 
dosing schedule of Prevnar 13™ (Group 1) 
with respect to the proportion of participants 
with adverse events (AEs).Followi ng an y vaccination with V114 or 
Prevnar 13™:
-Solicited injection -site AEs from Day  1 
through Day  14 postvaccination
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) through completion of s tudy 
participation
-Objective: To evaluate the anti -pneumococcal 
polysaccharide (PnPs) seroty pe-specific 
Immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at 30 day s following 
Dose 4 for participants administered mixed 
dosing schedules of Prevn ar13™/V114 
(Groups 2, 3, and 4) compared with 
participants administered a complete dosing 
schedule of Prevnar 13™ (Group 1).-Anti-PnPs seroty pe-specific IgG responses 
for the 13 shared serot ypes contained in V114 
and Prevnar 13™ at 30 days postdose 4 (P D4) 
  04ZGY9 
  05PZF8

PRODUCT: V114 11
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Secondary  Objectives Secondary  Endpoints
-Objective: To compare the proportion of 
participants with anti -hepatitis B surface 
antigen (HBsAg) concentration ≥10 mI U/mL 
at 30 day s following Dose 3 for participants 
administered a complete primary  infant series 
dosing schedule of V114 (Group 5) 
concomitantly  with RECOMBIVAX HB™ 
versus participants administered a complete 
primary  infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) concomitantl y 
with RECOMBIVAX HB™.
Hypothesis (H1): RECOMBIVAX HB™
administered concomitantly  with V114 is non -
inferior to RECOMBIVAX HB™ administered 
concomitantly  with Prevnar 13™ as measured 
by the proportion of participants with anti -
HBsAg concentration ≥10 mI U/mL at 30 day s 
following Dose 3.
(thestatistical criteri on for non -inferiority  
requires the lower bound of the 2 -sided 95% 
CI of the difference in proportions of 
participants with anti -HBsAg concentration ≥10 
mIU/mL [V114 minus Prevnar 13™] to be 
greater than -0.10)-Anti-HBsAg response at 30 day s postdose 3 
(PD3) of V114 or Prevnar 13™
-Objective: To compare the anti -rotavirus 
Immunoglobulin A (IgA) Geometric Mean 
Titer (GMT) at 30 day s following Dose 3 for 
participants administered a complete primary  
infant series dosing schedule of V114 (Group 
5) concomitan tly with RotaTeq™ versus 
participants administered a complete primary  
infant series dosing schedule of Prevnar 13™ 
(Groups 1 and 2) concomitantly  with 
RotaTeq™.
Hypothesis (H2): RotaTeq™ administered 
concomitantly with V114 is non -inferior to 
RotaTeq™ admi nistered concomitantly  with 
Prevnar 13™ as measured by  anti-rotavirus 
IgA GMT at 30 day s following Dose 3.
(thestatistical criterion for non -inferiority  
requires the lower bound of the 2 -sided 95% 
CI of the anti -rotavirus IgA GMT ratio -Anti-rotavirus IgA response at 30 day s PD3 
of V114 or Prevnar 13™ 
  04ZGY9 
  05PZF8

PRODUCT: V114 12
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
[V114/Prevnar 13™] to be greater than 0.50)
-Objectives: To evaluate the anti -PnPs 
seroty pe-specific IgG GMCs and the anti -PnPs 
seroty pe-specific IgG response rates 
(proportion of participants meeting sero type-
specific IgG threshold value of ≥0.35 μg/mL) 
at 30 day s following Dose 3 separatel y for each 
vaccination group (Groups 1, 2, 3, 4, and 5).-Anti-PnPs seroty pe-specific IgG responses 
for the 15 serot ypes contained in V114 at 30 
days PD3
-Objective: To evaluate the anti -PnPs 
seroty pe-specific IgG GMCs at 30 day s 
following Dose 4 for participants administered 
a complete dosing schedule of V114 (Group 5) 
compared with participants administered a 
complete dosing schedule of Prevnar 13™ 
(Group 1).-Anti-PnPs seroty pe-specific IgG responses 
for the 13 shared serot ypes contained in V114 
and Prevnar 13™ at 30 day s PD4
Overall Desig n:
Study  Phase Phase 3
Primary  Purpose Prevention
Indication Pneumococcal disease
Population Health y infant s
Study  Type Interventional
Intervention Model Parallel
This is a multi -sitestudy .
Type of Control Active control without placebo
Study  Blinding Double -blind
Masking Participant
Care Provider
Investigator 
  04ZGY9 
  05PZF8

PRODUCT: V114 13
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Estimated Duration o f Study The Sponsor estimates that the study  will require 
approximately 25 months from the time that written 
informed consent is provided for the first participant until the 
last participant’s last study -related telephone call or visit.
For purposes of analy sis and reporting, the overa ll study  
ends when the Sponsor receives the last laboratory result or 
at the time of final contact with the last pa rticipant, 
whichever comes last .
Number of Participant s:
Approximately  900participants will be randomized, with approximately  180 participants in each 
intervention group.
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group Name VaccineDose 
StrengthDose 
FrequencyRoute 
of 
Admin.Vaccination 
Regimen Use
1 Prevnar 13™Refer to 
product 
labeling4 doses IMSingle dose at Visits 
1, 2, 3, and 5 (~2, 4, 
6, and 1 2to 15 
months of age, 
respectively)Experimental
2Prevnar 13™Refer to 
product 
labeling3 doses IMSingle dose at Visits 
1, 2, and 3 (~2, 4, 
and 6 months of age, 
respectively)Experimental
V114Refer to 
IBSingle dose IMSingle dose at Visit 5 
(~12to 15 months of 
age)Experimental
3Prevnar 13™Refer to 
product 
labeling2 doses IMSingle dose at Visits 
1 and 2 (~2 and 4 
months of age, 
respectively)Experimental
V114Refer to 
IB2 doses IMSingle dose at Visits 
3 and 5 (~6 and 1 2 to 
15 months of age, 
respectively)Experimental
4Prevnar 13™Refer to 
product 
labelingSingle dose IMSingle dose at Visit 1 
(~2 months o fage)Experimental
V114Refer to 
IB3 doses IMSingle dose at Visits 
2, 3, and 5 (~4, 6, 
and 1 2to 15 months 
of age, respectively)Experimental
5 V114Refer to 
IB4 doses IMSingle dose at Visits 
1, 2, 3, and 5 (~2, 4, 
6, and 1 2to 15 
months of age, 
respectively)Experimental
IB=Investigator’s Brochure; I M = intramuscular 
  04ZGY9 
  05PZF8

PRODUCT: V114 14
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Total 
Number5 intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  16to 20
months from the time the participant’s legall y acceptable representative
signs the Informed Consent F orm ( ICF) through the final contact.
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 7. 
  04ZGY9 
  05PZF8

PRODUCT: V114 15
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
1.2 Schema
The key components of the study  design aredepicted in Figure 1.
Figure 1V114 -027 Study  Design
 
  04ZGY9 
  05PZF8

PRODUCT: V114 16
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
1.3 Schedule of Activities (SoA)
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Administrative Procedures
Screening Procedures
Informed Consent
XConsent must be obtained 
before any study 
procedures.
Informed Consent for Future
Biomedical Research
XConsent for future 
biomedical research 
samples must be obtained 
before the collection of 
buccal swab DNA 
samples.
Assignment of Screening 
NumberX
Participant Identification Card X
Inclusion/Exclusion Criteria X
Medical History X
Post-Enrollment Procedures
Assignment of Randomization 
NumberX
Prior/Concomitant Medication 
and Non -Study Vaccination 
ReviewX X X X X X X X X X 
  04ZGY9 
  05PZF8

PRODUCT: V114 17
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
V114 or Prevnar 13™ 
Administration (Blinded)
X X X XBefore vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant ’s chart. 
At Visits 1, 2, 3, and 5, 
participants will receive 
either a single dose of 
V114 or Prevnar 13™. 
  04ZGY9 
  05PZF8

PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open -label)
 RotaTeq™
 Pentacel™
 RECOMBIVAX HB™
X X* XBefore vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant’s chart.
All participants will 
receive licensed 
concomitant vaccines 
according to the 
recommended schedule by 
the US ACIP. Non- US 
countries participating in 
thisstudy must follow the 
US vaccination schedule.
See Section 6.5 for details 
onconcomitant vaccines. 
  04ZGY9 
  05PZF8

PRODUCT: V114 19
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open -label), 
continued
 RotaTeq™
 Pentacel™
 RECOMBIVAX HB™
X X* XRotaTeq™ is 
administered orally and 
should be given before 
V114 or Prevnar 13™and 
other injectable 
concomitant vaccines.
Other injectable vaccines 
administered 
concomitantly should be 
given after V114 or 
Prevnar 13™.
*For participants who 
received the first dose of 
hepatitis B vaccine before
enrollment , 
RECOMBIVAX HB™
will be administered at ~2 
and 6 mo nths of age and 
not at ~4 months of age . 
The receipt of h epatitis B 
vaccine at birth needs to 
be reviewed and 
documented in the 
participant’s chart. 
  04ZGY9 
  05PZF8

PRODUCT: V114 20
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open -label)
 HIBERIX™
 M-M- R™ II 
 VARIVAX™
XBefore vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant’s chart.
All participants will 
receive licensed 
concomitant vaccines 
according to the 
recommended schedule by 
the US ACIP. Sites in 
non-US countries 
participating in the study 
must follow the US 
vaccination schedule. See 
Section 6.5 for details on 
concomitant vacci nes. 
  04ZGY9 
  05PZF8

PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open -label) , 
continued
 HIBERIX™
 M-M- R™ II 
 VARIVAX™XOther pediatric injectable 
vaccines administered 
concomitantly should be 
given after V114 or 
Prevnar 13™.
Provide eVRC
XParticipants will be 
provided an eVRC at 
Visit 1to record AEs,
body temperature 
measurements , 
concomitant medications, 
and non -study 
vaccinations. Instructions 
for using the eVRC will 
be reviewed with the 
participant’s legally 
acceptable representative .
Review eVRC Data with 
Participant’s L egally 
Acceptable RepresentativeX X X X X X X X XSee Section 8.1.10 for 
details.
Complete the Telephone 
Contact Questionnaire XThe Telephone Contact 
Questionnaire will be 
provided by the Sponsor.
Collect eVRC from 
ParticipantX 
  04ZGY9 
  05PZF8

PRODUCT: V114 22
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Safety Procedures
Complete Physical 
ExaminationXTo be performed by the 
investigator or medically 
qualified designee before 
vaccine is administered.
Targeted Physical 
ExaminationX X XTo be performed by the 
investigator or medically 
qualified designee before 
vaccine is administered. 
  04ZGY9 
  05PZF8

PRODUCT: V114 23
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Body Temperature 
Measurement
X X X XEach participant ’s body 
temperature must be taken 
before vaccination. 
Participants who have 
febrile illness (rectal 
temperature ≥38.1°C 
[≥100.5°F] or axillary 
temperature ≥37.8°C 
[≥100.0°F]) occurring at 
or within 72 hours of 
Visits 1, 2, 3 and 5 must 
be rescheduled.
Participant’s legally 
acceptable representative
willrecord a rectal 
temperature on the eVRC 
from Days 1 through 7 
following each 
vaccination and Days 8 
through 14 (if fever is 
suspected) . 
  04ZGY9 
  05PZF8

PRODUCT: V114 24
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
30-Minute Postvaccination 
Observation Period X X X XTo be performed by 
blinded study site 
personnel only.
AE Monitoring
X X X X X X X X X X XAEs (serious and non -
serious) are to be reported 
from Days 1 through 14 
following each 
vaccination. SAEs and 
deaths are to be reported 
throughout the duration of 
an individual’s study 
participation.
Immunogenicity Procedures
Serum for Immunogenicity 
Assays (Including Retention 
Serum)X X XBlood samples must be 
collected before 
vaccination.  
  04ZGY9 
  05PZF8

PRODUCT: V114 25
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Period Intervention Follow -up Comments
Visit Number: 1 TC 2 TC 3 TC 4 5 TC 6 TC
Scheduled Time: Age: ~2 
months
Dose 1Day 
15 
after 
Dose 
1Age: ~4 
months
Dose 2Day 
15 
after 
Dose
2Age: ~6 
months
Dose 3Day 
15 
after 
Dose
3~1 
month 
after 
Dose 
3Age: ~12 
to 15 
months
Dose 4Day 
15 
after 
Dose 
4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Windowa: ≥42 
days of 
age to 
≤90 
days of 
ageDay 
15 to 
Day 
19
Post
dose
14 months 
of age to 
1 day 
prior to 5 
months of 
ageDay 
15 to 
Day 
19
Post
dose
26 months 
of age to 
1 day 
prior to 7 
months of 
ageDay 
15 to 
Day 
19
Post
dose
3Day 
28 to
Day 
42 
Post
dose 312 months 
of age to 1 
day prior 
to 16 
months of 
ageDay 
15 to 
Day 
19
Post
dose
4Day 28 
to Day 
42 Post
dose 4Day 
166 to 
Day 
194 
Post
dose 4
Future Biomedical Research
Collect Buccal Swabs for 
Future Biomedical Research
XBuccal swab DNA 
samples for analysis 
should be obtained prior 
to the vaccination at 
Visit 1, onrandomized 
participants only, or at a 
later date as soon as the 
informed consent is 
obtained.
aFor calculating the visit windows, the day of vaccination i sconsidered Day 1. To calculate visit windows for subsequent vaccinations, confirm subject date of birth and ensure 
the age of the subject will fall within the appropriate age range for each study visit.
ACIP = Advisory Committee on Immunization Practices ; AE =adverse event; DNA =deoxyribonucleic acid ; eVRC =electronic Vaccination Report Card ; SAE = serious adverse 
event; TC= telephone contact ; US = United States 
  04ZGY9 
  05PZF8

PRODUCT: V114 26
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
2 INTRODUCTION
Merck Sharp & Dohme Corp. (MSD) is developing an investigational 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for the prevention of 
pneumococcal disease caused by  the serot ypes in the vaccine. V114 contains the 13 serot ypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in the licensed vaccine 
Prevnar 13™ (pneumococcal 13 -valen t conjugate vaccine [diphtheria CRM 197protein ], 
Wyeth Pharmaceuticals, a subsidiary  of Pfizer, Inc., Philadelphia, PA) , plus 2 additional 
seroty pes (22F, 33F) .
2.1 Study Rationale
Despite the availabilit y of pneumococcal conjugate vaccine s(PCVs) , pneumococcal disease
remains a concern as non -vaccine serot ypes began to appear in increasing frequency in 
invasive pneumococcal disease (IPD) isolates. Given the importance of pneumococcal
disease worldwide, the evolving serot ype distribution ,and the val ue of multiple suppliers to 
strengthen global supply , there is a continued need to develop new PCVs with expanded 
seroty pe coverage. V114 includes 2key additional seroty pes compared with Prevnar 13™
andwill address an unmet medical and public health need for a PCV with expanded 
coverage . 
This clinical study , to be conducted in healthy  infants approximately  2 months of age (42 to 
90 day s of age ),is part of a Phase 3 pediatric clinical program to support an initial 
registration of V114 for use in healthy  infants and children fortheprevention of 
pneumococcal disease caused by the 13 pneumococcal serotypes contained in Prevnar 13™
and 2 additional unique seroty pes (22F and 33F )inV114.  
Thepurpose of this stud y is to describe the safet y and immunogenicit y of a 4-dose schedule 
(3 infant primary  series followed by 1 toddler dose) of PCV when switching from 
Prevnar 13™ to V114 at Doses 2, 3, or 4 during the immunization schedule.
Currently  availa ble licensed PCVs have not shown any  clinicall y relevant interference when 
administered concomitantly  with other pediatric vaccines. With the exception of some 
countries/regions (eg, Italy and Spain where PCVs are not given simultaneously  with 
vaccines to prevent influenza or meningitis), licensed PCVs are recommended to be given at 
the same time as other recommended pediatric vaccines. The concomitant administration of 
V114 with recommended pediatric vaccines will be evaluated as part of the Phase 3 pediatric
clinical program .This study  will evaluate the concomitant administration of V114 and the 
licensed pediatric vaccines ,RECOMBIVAX HB™ and RotaTeq™.
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB)for V114 for de tailed background, including 
information on pneumococcal disease burden . 
  04ZGY9 
  05PZF8

PRODUCT: V114 27
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Streptococcus pneumoniae remains a significant cause of disease worldwide, with clinical 
manifestations including meningitis, sepsis, pneumonia, sinusitis, and otitis media .
Currently , man y countries worldwide have incorporated licensed PCVs (eg, Prevnar 13™ 
and/or Synflorix™ [pneumococcal pol ysaccharide conjugate vaccine [adsorbed], 
GlaxoSmithKline Biologicals S.A, Rixensart, Belgium] ) into their infant immunization 
programs. Prevnar™ was first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 
(European Union )and 2010 (United States ). Synflorix™ was licensed in the European Union 
in 2009. Although Prevnar 13™ is indicated for children and adults, Sy nflorix™ is only  
indicated for children up to 5 y ears of age. Widespread use of PCVs have reduced the burden 
of pneumococcal disease due to the serot ypes contained in the vaccines in children who 
received the vaccin es,as well as unvaccinated individuals through herd protection [Centers 
for Disease Control and Prevention 2 008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 
2007] [Pilishvili, Tamara, et al 2010] [L exau, C. A., et al 2005] [Metlay , J. P., et al 2006] 
[Whitney , Cynthia G., et al 2003] [Moore, M. R., et al 2015] [Lepoutre, A., et al 2015] 
[Weiss, S., et al 2 015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et 
al 2015] [Jokinen, J., et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] . 
Despite this, an increase in the burden of invasive pneumococcal disease (IPD) caused b y 
seroty pes not contained in currentl y available vaccines has been observed.
V114 contains all the pneumococcal serot ypes contained in Prevnar 13™ plus 2additional 
seroty pes (22F, 33F). The selection of 22F and 33F was primarily  based on the emerg ence of 
these 2 serot ypes as important causes of invasive pneumococcal disease in the era of 
Prevnar™ and Prevnar 13™. A pproximately  4 years after inclusion of Prevnar™ in the US
infant immunization schedule, serotypes 22F and 33F accounted for approximate ly 13% of 
IPD cases in children <5 years of age (incidence rate of IPD due to 22F and 33F of 3.1 cases 
per 100,000 person -years [ PY]),in contrast to 1.3% of IPD cases in the pre -Prevnar™ era 
(incidence rate of IPD due to 22F and 33F of 1.2 cases per 100,0 00 PY) [Hicks, L . A., et al 
2007] . By 2013, both 22F and 33F were among the leading serot ypes causing IPD bey ond 
those alread y included in Prevnar 13™ , accounting for approximately 21% of all I PD in 
children < 5 years of age in the US[Moore, M. R., et al 2015] . 
The additional serot ypes contained in V114 will provide broader coverage against the leading 
seroty pes associated with pneumococcal disease worldwide. V114 i s designed to meet 
continuing medical and public health needs for PCVs globall y, as well as address the 
emergence of pneumococcal disease caused b y serotypes not contained in currentl y licensed 
PCVs.
2.2.2 Preclinical and Clinical Studies
Refer to the IB for inf ormation on completed preclinical and clinical studies conducted with 
V114. 
  04ZGY9 
  05PZF8

PRODUCT: V114 28
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
2.2.3 Information on Other Study -related Therapy
Refer to approved labeling for detailed background information on Prevnar 13™ and other 
licensed pediatric vaccines administered concomit antly .
Prevnar 13™ contains the 7 pneumococcal serotypes included in Prevnar™ (4, 6B, 9V, 14, 
18C, 19F, 23F) plus 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A).
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar13™ in many  
countries outside of the US; these vaccines will be referred to as Prevnar™ and Prevnar 13™ 
throughout this document.
Licensed pediatric vaccines will be provided and administered concomitantly according to 
the recommended schedule by the US AC IP(Table 3).Note: Non -US countries participating 
in the study  must follow the US recommended pediatric vaccination schedule.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safet y and efficacy of an investigational medicine.
Approximately  20% of par ticipants will receive 4 doses of Prevnar 13™, the standard of 
care, as the active comparator in this study. Approximately  20% of participants will receive 
4doses of V114 and 60% of participants will receive 4 doses of mixed V114 and Prevnar 13 
dosing schedules . V114 is expected to provide comparable immune responses and safety  
profile to Prevnar 13™ for the shared pneumococcal serot ypes while providing additional 
coverage for the 2 serot ypes (22F and 33F) unique to V114. It is unknown if the 
investigational V114 will have the same benefit /risk profile as Prevnar 13™.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompan ying IB and Informed Consent F orm ( ICF).
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
The following h ypotheses, objectives and endpoints will be evaluated in healthy infants 
administered V114 or Prevnar 13™ in 1 of 5 intervention groups:
Group 1 : Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3 : Prevnar 13™ →Prevnar 13™ → V114 →V114
Group 4 : Prevnar 13™ →V114 →V114 →V114
Group 5 : V114 →V114 →V114 →V114 
  04ZGY9 
  05PZF8

PRODUCT: V114 29
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Objectives Endpoints
Primary
•Objective : To evaluate the safet y and 
tolerability  of complete V114 (Group 5)
and mixed Prevnar 13™/V114 dosing 
schedule s (Groups 2, 3,and 4) compared
with a complete dosing schedule of 
Prevnar 13™ (Group 1) with respect to 
the proportion of participants with 
adverse events (AEs).Following any vaccination with V114 or 
Prevnar 13™ :
•Solicited injection -site AEs from Day  1 
through Day  14 postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related serious adverse events 
(SAEs) through completion of study
participation
•Objective : To evaluate the anti -
pneumococcal poly saccharide (PnPs) 
seroty pe-specific Immunoglobulin G 
(IgG) Geometric Mean Concentrations 
(GMCs) at 30 day s following Dose 4 for 
participants administered mixed dosing 
schedules of Prevnar 13™/V114 (Groups 
2, 3, and 4) compared with participants 
administered a complete dosing sc hedule
of Prevnar 13™ (Group 1) .•Anti-PnPs seroty pe-specific IgG 
responses for the 13shared serot ypes
contained inV114 and Prevnar 13™ at 
30 day s postdose 4 (PD4)
Secondary
Objective :To compare the proportion of 
participants with anti -hepatitis B surface 
antigen (HBsAg) concentration ≥10 
mIU/mL at 30 day s following Dose 3 for 
participants administered a complete 
primary  infant series dosing schedule of 
V114 (Group 5) concomitantly  with 
RECOMBIVAX HB™ versus 
participants administered a complete 
primary  infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitan tly with RECOMBIVAX 
HB™.
Hypothesis (H1): RECOMBIVAX HB™ 
administered concomitantly  with V114 is 
non-inferior to RECOMBIVAX HB™ 
administered concomitantly  with Anti-HBsAg response at 30 day s 
postdose 3 ( PD3)of V114 or 
Prevnar 13™ 
  04ZGY9 
  05PZF8

PRODUCT: V114 30
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Prevnar 13™ as measured by  the 
proportion of participants with anti -
HBsAg concentration ≥10 mI U/mL at 30 
days following Dose 3 .
(thestatistical criterion for non -inferiority  
requires the lower bound of the 2 -sided 95% 
CI of the difference in proportions of 
participants with anti -HBsAg 
concentration ≥10 mI U/mL [V114 minus 
Prevnar 13™] to be greater th an -0.10)
•Objective : To compare the anti -rotavirus 
Immunoglobulin A (IgA) Geometric 
Mean Titer (GMT) at 30 day s following 
Dose 3 for participants administered a 
complete primary  infant series dosing 
schedule of V114 (Group 5) 
concomitantly  with RotaTeq™ versus 
participants administered a complete 
primary  infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitantly  with RotaTeq™.
Hypothesis (H2): RotaTeq™ 
administered concomitantly  with V114 is 
non-inferior to RotaTeq™ administered 
concomitantly  with Prevnar 13 ™as 
measured b y anti-rotavirus IgA GMT at 
30 day s following Dose 3.
(thestatistical criterion for non-inferiority  
requires the lower bound of the 2 -sided 95% 
CI of the anti -rotavirus IgA GMT ratio 
[V114/Prevnar 13™] to be greater than 0.50)Anti-rotavirus IgA response at 30 day s 
PD3 of V114 or Prevnar 13™
Objective s: To evaluate the anti -PnPs 
seroty pe-specific IgG GMCs and the anti -
PnPs seroty pe-specific IgG response rates 
(proportion of participants meeting 
seroty pe-specific IgGthreshold value of 
≥0.35 μg/mL ) at 30 day s following 
Dose 3separatel yfor each vaccination 
group (Groups 1, 2, 3, 4, and 5) .•Anti-PnPs seroty pe-specific IgG 
responses for the 15 seroty pescontained 
in V114 at 30 day s PD3 
  04ZGY9 
  05PZF8

PRODUCT: V114 31
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
•Objective : To evaluate the anti -PnPs 
seroty pe-specific IgG GMCs at 30 day s 
following Dose 4 for participants 
administered a complete dosing schedule 
of V114 (Group 5) compared with 
participants administered a complete 
dosing schedule of Prevnar 13™ (Group 
1).•Anti-PnPs seroty pe-specific IgG 
responses for the 13 shared serot ypes
contained in V114 and Prevnar 13™ at 
30 day s PD4
Tertiary /Exploratory
•Objective : To evaluate the anti -PnPs 
seroty pe-specific IgG GMCs prior to 
Dose 4 separatel yfor each vaccination 
group (Groups 1, 2, 3, 4, and 5).•Anti-PnPs s eroty pe-specific IgG 
responses for the 15 seroty pescontained 
in V114 prior to Dose 4 (pre-dose 4 )
•Objective : To evaluate the anti-HBsAg 
GMCs at 30 day s following Dose 3 for 
participants administered a complete 
primary  infant series dosing schedule of 
V114 (Group 5) concomitantly  with 
RECOMBIVAX HB™ versus 
participants administered a complete 
primary  infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitantly  with 
RECOMBIVAX HB™.•Anti-HBsAg response at 30 day s PD3 of 
V114 or Prevnar 13™
4 S TUDY DESIGN
4.1 Overall Design
Approximately  900 healthy  infants will be randomly  assigned ,in a 1:1:1:1:1 ratio ,to 1 of 5 
vaccination groups (180 per group) ( Table 1)
.Randomization will be stratified by  previous 
hepatitis B vaccination status . All participants will receive other licensed pediatric vaccines 
administered concomitan tly according to the recommended schedule by the USACIP (Table 
3).Note: Non -US countries participating in the study  must follow the US vaccination 
schedule.
Participants will be followed for local and s ystemic AEs through Day  14 following each 
vaccination with V114 or Prevnar 13™ . Information for SAEs and deaths, regardless of 
whether the events are considered to be vaccine -related by  the investigator, will be collected 
from the time consent is signed through completion of participation in the study .An ex ternal 
Data Monitoring Committee (DMC) will conduct a periodic review of safety  and tolerability  
data for the V114 Phase 3 pediatric program. A description of the structure, function, and 
guidelines for decision -making by  the DMC, along with the timing and content of the safety   
  04ZGY9 
  05PZF8

PRODUCT: V114 32
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
reviews will be outlined in the DMC charter. Information regarding the composition of the 
DMC is provided in Appendix 1.
Blood samples for immunogenicity  assay s will be drawn at 3 timepoints: (1) 30 day s 
Postdose 3 , (2) immediately  prior to Dose 4 , and (3) 30 day s Postdose 4 .
After completion of immunogenicity  testing (including electrochemiluminescence [ECL ]
testing to measure V114 or Prevnar 13™ -induced pneumococcal -specific immune responses, 
anti-HBsAg concentration measurement, and anti-rotavirus IgA measurement ), serum 
samples will be stored to conduct an y additional study -related testing as required by  
regulatory  agencies or the Sponsor. For randomized study  participants who provided consent 
forFuture Biomedical Research, leftover sera from the study  may  be used for the 
development and/or validation of pneumococcal assays after completion of all study -related 
immunogenicit y testing .
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
Table 1 V114/Prevnar 13™ Dosing Schedule
Intervention 
Group NameDose 1 ( Visit 1, ~2 
months of age)Dose 2 ( Visit 2, ~4 
months of age)Dose 3 ( Visit 3, ~6 
months of age)Dose 4 ( Visit 5, ~12 to 
15 m onths of age)
≥42 days of age to 
≤90 days of age4 months of age to 
1day prior to 
5months of age6 months of age to 
1day prior to 
7months of age12 m onths of age to 
1day prior to 
16months of age
Group 1 Prevnar 13™ Prevnar 13™ Prevnar 13™ Prevnar 13™
Group 2 Prevnar 13™ Prevnar 13™ Prevnar 13™ V114
Group 3 Prevnar 13™ Prevnar 13™ V114 V114
Group 4 Prevnar 13™ V114 V114 V114
Group 5 V114 V114 V114 V114
4.2 Scientific Rationale for Study Design
This study  will be conducted in health y infants approximately  2 months of age (42 to 90 day s 
of age) . These infants are at increased risk for pneumococcal disease and its associated 
morbidity  and mortality  [Drijkoningen, J. J 2014] .In addition, the enrol lment of infants is 
intended to asses ssafety , tolerability ,and immunogenicity  in a population th at is 
representative of children receiving licensed PCVs and the recommended concomitant 
pediatric vaccines in the US and non-UScountries .
This study  is designed to evaluate the safet y and immunogenicit y of mixed PCV regimens in 
which the pneumococcal imm unization series is initiated with Prevnar 13™and is chang ed 
to V114 at Dose 2, 3 or 4. Data from this study  will support the safet y and immunogenicit y  
  04ZGY9 
  05PZF8

PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
of switching to V114 at any time during the immunization s eries in settings where 
Prevnar 13™ is alread y widely  used.
The safet y and immunogenicity  endpoints are consistent with previous studies evaluating the
interchangeability  of PCVs and immunogenicit y of hepatitis B and rotavirus vaccines when 
PCVs are given concomitantly .Data from t his study  will also contribute to the overall safet y 
database and immunogenicity  profile of V114 to support initial licensure in infants.
4.2.1 Rationale for Endpoints
4.2.1.1 Immunogenicity Endpoints
Previous studies have evaluated the interchangeability of PCVs [Truck, J., et al 2016] 
[Ciapponi, A., et al 2016] .These studies evaluated the immune responses and reactogenicit y 
in infants primed with Prevnar 13™ andboosted with Synflorix™ (as compared with a 
Prevnar 13™ booster) and in infants primed wi th Prevnar™ and boosted with Prevnar 13™. 
The primary  immunogenicity  endpoint of these interchangeability  studies were assessed 1 
month after the administration of the last scheduled dose of the PCVs.
This study  will evaluate the safet y, tolerability , and immunogenicit y of the interchangeability 
between V114 and Prevnar 13™ in participants administered mixed dosing schedules of 
Prevnar 13™ and V114 (Groups 2, 3, and 4) compared with participants administered a 
complete dosing sch edule of Prevnar 13™ (Group 1).
Sera from participants will be used to measure vaccine -induced anti -PnPs seroty pe-specific 
IgG for the 13 shared seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 
contained in V114 and Prevnar 13™ at 30 day s after Dose 4. The primary  interchangeability  
immunogenicit y endpoint will be assessed after completion of the full PCV regimen. Anti -
PnPs seroty pe-specific IgG responses will also be measured at 30 day s following completion 
of the primary  infant series and prior toDose 4 to evaluate the anamnestic antibody  
responses and the persistence of protective immunity .
Sera from participants will also be used to measure anti HBsAg concentration using the 
hepatitis B enhanced che miluminescence (ECi) assay . An anti-HBsAg con centration of 
≥10mIU/mL measured 1 to 3 months after administration of the last dose of the primary  
3-dose vaccination series is considered a reliable marker of protection against hepatitis B 
infecti on [Van Damme, P. 2016] . In this study , infants will receive a total of 3 hepatitis B 
vaccinations (2, 4 and 6 months). For those participants who received the first dose of 
hepatitis B vaccine prior to enrollment in the study, hepatitis B vaccine will be administered 
at 2 and 6 mont hs of age and not at 4 months. Because antibod y responses and GMTs may  be 
slightly  higher when hepatitis B vaccination is initiated after 1 month of life [Schillie, S. F. 
2013] ,rando mization in this study  will be stratified by  previous hepatitis B vaccination status 
before enrollment.
Sera from participants will also be used to measure anti -rotavirus IgA using the enzy me-
linked immunosorbent assay  (EIA). Serum anti- rotavirus IgA is a marker of protection  
  04ZGY9 
  05PZF8

PRODUCT: V114 34
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
against rotavirus infection and moderate -to-severe diarrhea [Velázquez, F. R., et al 2000] . 
Following rotavirus vaccination, there is a correlation between serum anti -rotavirus IgA 
GMT ratio s following D ose 3 and protective immunity  at the population level [Liu, G. F., et 
al 2017] .
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1 .
4.2.1.2 Safety Endpoints
The sa fety endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during product development. The electronic Vaccin ation 
Report Card (eVRC) used to record AEs during the postvaccination periods, as defined in 
Section 8.1.9, was structured as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] .
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3.3and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
4.2.1.3 Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as par t of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understa nding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect t ime. The 
details of this future biomedical r esearch substudy  are presented in Appendix 5.
4.2.2 Rationale for the Use of Comparator
Placebo -controlled clinical studies for new PCVs are no longer acceptable given the proven 
clinical efficacy , public health impact ,and widespread use of licensed PCV sworldwide. 
Prevnar 13™ is currentl y the most widely recommended vaccine for the prevention of  
  04ZGY9 
  05PZF8

PRODUCT: V114 35
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
pneumococcal disease in infants in many  countries worldwide ,includes the largest number of 
seroty pes,and will be used as the active comparator in this study .
Refer to approved labeling for detailed background information on Prevnar 13™.
4.3 Justification for Dose
The dose and dosing schedule of V114 is similar to that used in previous pediatric V114 
clinical studies ,which demon strated safet y andcomparable immune response s to those of 
Prevnar 13™ .Refer to V114 IB for details on dosing schedule .
In order to support initial licensure in countries that use either the 3+1 Prevnar 13™ dosing 
schedule (3 doses in the infant primary  series followed by 1 toddler dose) or the 2+1 
Prevnar 13™ dosing schedule (2 doses in infant primary  series followed by 1 toddler dose), 
this study  will use the currentl y approved dose and US ACIP recommended 3+1 dosing 
schedule of Prevnar 13™.
4.4 Beginning and End of Study Definition
The overall study  begins when written informed consent is provided for the first participant. 
The overall study  ends when the last participant completes the last study -related telephone -
call or visit, withdraws from the study, or is lost to follow -up (ie, the participant is unable to 
be contacted b y the investigator).
For pu rposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last laboratory result or at the time of final contact with the last participant, whichever comes 
last.
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical stud y may be terminated earl y if the extent (incidence and/or severit y) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particu lar 
study  site(s) may  be stopped due to insufficient compliance with the protocol, Good Clinical 
Practice ( GCP ), and/or other applicable regulatory requirements, procedure -related problems 
or an unacceptabl y high number of discontinuations or withdrawals d ue to administrative 
reasons.
5 STUDY POPULATION
Health ymale and female infants approximately  2 months of age, from 42 and 90 day s 
(inclusive) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted. 
  04ZGY9 
  05PZF8

PRODUCT: V114 36
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.Participant is healthy  (based on a review of medical history  and physical examination)
based on the clinical judgement of the investigator .
Demographics
2.Participant is male or female infant approximately  2 mont hs of age, from 42daysto 90
daysinclusive, at the time of obtaining the informed consent.
Informed Consent
3.Participant has a legally  acceptable representative who understands the study procedures, 
alternate treatments available, and risks involved with the study and voluntarily  agrees to 
participate b y giving written informed consent. The legall y acceptable rep resentative may 
also provide consent for future biomedical research. However, the participant may  
participate in the main study without participating in future biomedical research.
5.2 Exclusion Criteria
Participants are excluded from the study if an y of the f ollowing criteria apply :
Medical Conditions
1.Has a history  of invasive pneumococcal disease (positive blood culture, positive 
cerebrospinal fluid culture, or other sterile site) or known history of other culture positive 
pneumococcal disease.
2.Has a known hypersensitivity  to any  component of the pneumococcal conjugate vaccine 
(PCV) , any component of the licensed pediatric vaccines to be administered 
concomitantly  in the study , or any  diphtheria toxoid -containing vaccine.
3.Has an y contraindication to the concom itant study vaccines being administered in the 
study (concomitant vaccine contraindication details provided in the Investigator Trial File 
Binder) .
4.*Had a recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary  
temperature ≥37.8°C [≥100.0°F]) occurring within 72 hours prior to receipt of study 
vaccine.
5.Has a known or suspected impairment of immunological function.
6.Has a history  of congenital or acquired immunodeficiency .
7.Has or his/her mother has a documented human immunodeficiency  virus (HIV) infection. 
  04ZGY9 
  05PZF8

PRODUCT: V114 37
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.Has or his/her mother has a documented hepatitis B surface antigen –positive test.
9.Has known or history  of functional or anatomic asplenia.
10.Has failure to thrive based on the clinical judgement of the investigator .
11.Has a known coagu lation disorder contraindicating intramuscular vaccination.
12.Has a history  of autoimmune disease (including but not limited to systemic lupus 
erythematosus, antiphospholipid sy ndrome, Behcet’s disease, autoimmune thy roid 
disease, pol ymyositis and dermatomyo sitis, scleroderma, t ype 1 diabetes mellitus, or 
other autoimmune disorders ).
13.Has a known neurologic or cognitive behavioral disorder, including encephalitis/my elitis, 
acute disseminating encephalomy elitis, pervasive development disorder, and related 
disorders.
Prior/Concomitant Therapy
14.Has received a dose of any pneumococcal vaccine prior to study  entry .
15.Has received >1 dose of monovalent hepatitis B vaccine or hepatitis B based combination 
vaccine prior to study  entry .
16.Has received a dose of rotavirus va ccine prior to study  entry .
17.*Meets one or more of the following s ystemic corticosteroid exclusion criteria:
a.Has received s ystemic corticosteroids (equivalent of ≥2 mg/kg total dail y dose of 
prednisone or ≥20 mg/d for persons weighing >10 kg) for ≥14 consecutive day s and 
has not completed this course of treatment at least 30 days prior to study 
randomization.
b.Has received s ystemic corticosteroids within 14 day s prior to the first dose of vaccine 
at randomization.
c.Is expected to require systemic cortico steroids within 30 day s after each vaccination 
during conduct of the study .
Note : Topical, ophthalmic and inhaled steroids are permitted.
18.*Has received other licensed non -live vaccines within the 14 day s before receipt of first 
dose of study  vaccine.
19.*Has received a licensed live virus vaccine within the 30 day s prior to receipt of first 
dose of study  vaccine. 
  04ZGY9 
  05PZF8

PRODUCT: V114 38
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
20.Has received a blood transfusion or blood products, including immunoglobulins.
Prior/Concurrent Clinical Study Experience
21.Has participated in anoth er clinical study of an investigational product before the 
beginning or an ytime during the duration of the current clinical study . Participants
enrolled in observational studies may be included; these will be reviewed on a 
case-by-case basis for approval b y the S ponsor .
Other Exclusions 
22.Has an y other reason that ,in the opinion of the investigator ,may interfere with the 
evaluation required b y the study. Reasons may  include ,but are not limited to ,being 
unable to keep appointments or planning to relocate during the stud y.
23.Is or has an immediate family  member (eg, parent/legal guardian orsibling) who is 
investigational site or Sponsor staff directly involved with this study .
For items with an aster isk (*), if the participant meets these exclusion criteria, Visit 1
may be rescheduled for a time when these criteria are not met.
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants whose legally  acceptable representative provides
consent to participate in the clinical study, but are not subsequently randomized in the study . 
A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure parti cipants to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory authorities . 
Minimal information includes demograph y, screen failure details, eligibility criteria, and any 
AEs or SA Es meeting reporting requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced .
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol. 
  04ZGY9 
  05PZF8

PRODUCT: V114 39
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Clinical supplies (V114 ,Prevnar 13™ , and concomitant vaccines listed in Table 3)will be 
packaged to support enrollment .Clinical supplies will be affixed with a clinical label in 
accordance with regulatory  requirements. 
  04ZGY9 
  05PZF8

PRODUCT: V114 40
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
6.1 Study Intervention(s) Administered
The blinded study interventions to be used in this study are outlined inTable 2.Licensed pediatric vaccines will be administered 
concomitantly  across all intervention groups; r efer to Table 3for dosing schedule and refer to product labeling for dose formulation, 
dose strength, dosage level, etc.
Table 2 Study  Intervention s
Arm 
Name Arm TypeIntervention 
Name TypeDose 
Form ulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adm in Vaccination Regimen UseIMP/N
IMPSourcing
1 Active 
ComparatorPrevnar 13™ Biological/
VaccineSterile 
suspensionRefer to 
product 
labeling0.5 mL IM Single dose at Visits 1, 2, 
3, and 5 (~2, 4, 6, and 12 
to 15 months of age, 
respectively)Experimental IMP Central
2 Experimental Prevnar 13™ Biological/
VaccineSterile 
suspensionRefer to 
product 
labeling0.5 mL IM Single dose at Visits 1, 2, 
and 3 (~2, 4, and 6 
months of age, 
respectively)Experimental IMP Central
V114 Biological/
VaccineSterile 
suspensionRefer to I B 0.5 mL IM Single dose at Visit 5 
(~12 to 15 months of age)Experimental IMP Central
3 Experimental Prevnar 13™ Biological/
VaccineSterile 
suspensionRefer to 
product 
labeling0.5 mL IM Single dose at Visits 1 
and 2 (~2 and 4 months 
of age, respectively)Experimental IMP Central
V114 Biological/
VaccineSterile 
suspensionRefer to I B 0.5 mL IM Single dose at Visits 3 
and 5 (~6 and 12 to 15 
months of age, 
respectively)Experimental IMP Central
4 Experimental Prevnar 13™ Biological/
VaccineSterile 
suspensionRefer to 
product 
labeling0.5 mL IM Single dose at Visit 1 (~2 
months ofage)Experimental IMP Central
V114 Biological/
VaccineSterile 
suspensionRefer to I B 0.5 mL IM Single dose at Visits 2, 3, 
and 5 (~4, 6, and 12 to 15 
months of age, 
respectively)Experimental IMP Central
5 Experimental V114 Biological/
VaccineSterile 
suspensionRefer to I B 0.5 mL IM Single dose at Visits 1, 2, 
3, and 5 (~2, 4, 6, and 12 
to 15 months of age, 
respectively)Experimental IMP Central
Admin =administration; I B =Investigator’s Brochure; I M = intramuscular; I MP=investigational medicinal p roduct; NI MP=non-investigational medicinal p roduct
The definition of I MP and NI MP is based on guidance issued by the European Commission. Regional and/or country differences of the definition of IMP/NI MP may exist. I n these circ umstances, local 
legislation is followed. 
  04ZGY9 
  05PZF8

PRODUCT: V114 41
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
All supplies indicated in Table 2will be provided per the "Sourcing" column depending upon 
local country  operational requirements. Every  attempt should be made to source these 
supplies from a single lot/batch number.
Refer t o Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose t o each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3.
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during tra nsit for all study  intervention received, and an y discrepancies are 
reported and resolved before use of the stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff .
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all st udy sites, the local country  Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate , the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interven tions in accordance with the protocol and any applicable laws and regulations. 
  04ZGY9 
  05PZF8

PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 5study  intervention arms. Participants will be assigned 
randomly  in a 1:1:1:1:1 ratio to the study  intervention listed in Table 2.
6.3.2 Stratification
Intervention allocation/randomization will be stratified according to the following factors:
Hepatitis B vaccination status before enrollment (Yes, No)
Stratification by  hepatitis B vaccination status before enrollment is relevant for this s tudy
because the timing of the first dose of hepatitis B vaccine may have an effect on 
immunogenicit y evaluation of the secondary endpoint related to concomitant administration 
of RECOMBIVAX HB™ (see Section 4.2.1.1 for details) .
6.3.3 Blinding
Adouble -blinding technique will be used. V114 and Prevnar 13™ will be prepared and/or 
dispensed by  an unblinded pharmacist or unblinded qualified study  site personnel. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
willremain blinded to the group assignments .
Because V114 and Prevnar 13™ have a different appearance, a member of the study  site staff 
will be unblinded for the purposes of receiving, maintaining, preparing, and administering 
these study vaccines. Procedures for handling, preparing, and admin istering the unblinded 
vaccines are located in the Investigator Trial File Binder. 
In order to avoid bias, the unblinded study person nelwill have no further contact with study
participants for any study -related procedur es/assessments after administration of study  
vaccines, which includes all safet y follow -up procedures . Additionall y, blinded site 
personnel will not be present in t he exam ination room when study  vaccines are administered. 
Contact between participants and u nblinded study personnel after vaccination administration 
is strictly  prohibited .Blinded site personnel will be responsible for all safety  and 
immunogenicit y follow -up procedures after vaccine administration.
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and Merck Research Laboratories emplo yees 
directly  involved with the conduct of this study  will remain blinded to the participant -level 
intervention assignment.
See Section 8.1.13for a description of the method of unblinding a participant during the 
study  should such action be warranted. 
  04ZGY9 
  05PZF8

PRODUCT: V114 43
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™ vaccination at Visits 
1, 2, 3, and 5 and concomitant vaccinations listed in Table 3require consultation between the 
investigator and the Sponsor and written documentation of th e collaborative decision on 
participant management.
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y(see Section 5.2 for details) . If there is a clinical indication for an y 
medication or vaccination specificall y prohibited, di scontinuation from study  intervention 
may be required. The investigator should discuss any  questions regarding this with the 
Sponsor Clinical Director . The final decision on any supportive therap y or vaccination rests 
with the investigator and/or the participant ’s primary  physician. However, the decision to 
continue the participant on study  intervention requires the mutual agreement of the 
investigator, the Sponsor, and the participant ’s legally  acceptable representative .
If a medical condition requires the use of a prohibitive steroid regimen , immunoglobulin, 
blood, or blood products during a subject's participation in this study , one of the individuals 
listed on the Sponsor Contact Information page must be notified as soon as possible . Any 
concurrent medication or medical treatment must be recorded on the appropriate eCRF. It is 
important to record the use of an y analgesic or antipy retic medication that occurs on the day  
of vaccination on the eV RC and appropriate eCRF.
Other licensed pediatric vaccines will be administered conco mitantly  according to the 
recomm ended schedule (Table 3). In the US, the ACI P recommend s that hepatitis B vaccine 
should be given at birth; however, guidelines for non-US counties may  differ. For 
participants who received the first dose of hepatitis B vaccine before enrollment, 
RECOMBIVAX HB™ will be administered at ~2 and 6 months of age and not at ~4 months 
of age.
In addition to concomitant vaccines being provided in the study  (Table 3), other non -study  
pediatric vaccines may  be permitted according to local, region al, and/or country  
guidelines. If the participant is scheduled to receive an y other non -study  pediatric vaccin e, 
the investigator should discuss this with the Sponsor Clinical Director as soon as possible.
These vaccinations should be recorded on the appropriate eCRF.
During influenza season, it is anticipated that participants 6 months of age and older may  be 
given an influenza vaccine. Influenza vaccine should be administered either 7 day s prior to or 
15 day s after the administration of the study  vaccine. 
Concomitant vaccines (oral or injectable) should be administered on the same day as V114 or 
Prevnar 13™ . RotaTeq™ is administered orally and should be given before V114 or 
Prevnar 13™ and other injectable concomitant vaccines. Precautions must be taken to 
prevent choking during the administration of oral vaccines. Other pediatric injectable  
  04ZGY9 
  05PZF8

PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
vaccines administered concomitantly  should be given after V114 or Prevnar 13™ . To avoid 
any confounding results, concomitant injectable vaccines should not be administered in the 
same limb as V114 or Prevnar 13™ . Recommended injection -site location sfor V114 or 
Prevnar 13™ and concomitant injectable vaccines are listed in Table 4.
Documentation of which limb to use for the administration of study vaccine s must be 
recorded on the appr opriate eCRF. Injection -site AEs for V114 or Prevnar 13™ (and not for
the concomitant vaccines) are being reported in this study ; therefore, this information must 
also be recorded on the eVRC to inform the participant’s legally  acceptable representative of
the appropriate limb to monitor for AEs related to the V114 or Prevnar 13™. 
No other investigational compound or device may be administered at an y time during this 
study  without prior approval by  the Sponsor.
Table 3 Concomitant Vaccine Schedule
Vaccine Tradenamea
(Generic Name) IndicationVisit 1
(~2 m onths 
of age )Visit 2
(~4 m onths 
of age )Visit 3
(~6 m onths 
of age )Visit 5
(~12 to 15 
months of 
age)
RotaTeq™b
(Rotavirus Vaccine, Live, 
Oral, Pentavalent)Prevention of rotavirus 
gastroenteritisX X X
Pentacel™ (Diphtheria and 
Tetanus Toxoids and Acellula r 
Pertussis Adsorbed, 
Inactivated Poliovirus and 
Haemophilus b Conjugate 
(Tetanus Toxoid Conjugate) 
VaccinePrevention of 
diphtheria, tetanus, 
pertussis, poliomyelitis, 
and invasive disease
due to Haemophilus 
influenzae type bX X X
RECOMBIVAX HB™
(Hepatitis B Vaccine 
[Recombinant])Prevention of hepatitis 
B virus infectionX XcX
HIBERIX ™
(Haemophilus b Conjugate 
Vaccine [Tetanus Toxoid 
Conjugate])Prevention of invasive 
disease caused by 
Haemophilus influenzae
type bX
M-M- R™ II
(Measles, Mumps, and Rubella 
Virus Vaccine Live)Simultaneous 
vaccination against 
measles, mumps, and 
rubellaX
VARIVAX™
(Varicella Virus Vaccine Live)Prevention of varicella X
a Tradenames for concomitant vaccines may vary depending on where clinical supplies are sourced by the Sponsor.
bRotaTeq™ is administered orally and should be given before V114 or Prevnar 13™ and other injectable concomitant 
vaccines. 
cFor participants who received the first dose of hepatitis B vaccine before enrollment, RECOMBIVAX HB™ will be 
provided and administered concomitantly with V114 or Prevnar 13™. 
  04ZGY9 
  05PZF8

PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table 4 Recommended Injection -Site L ocation for Stu dy Interventions
Vaccine Recommended Injection Site
V114 or Prevnar 13™ Right thigh
Pentacel™ Left upper thigh
RECOMBIVAX HB™ Left lower thigh
M-M- R™ II Deltoid right arm
VARIVAX™ Deltoid left arm
HIBERIX™ Left thigh
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open -label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; random 
code/disclosure envelopes or lists are not provided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency  (see Section 8.1.1
3). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identi ty. The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.13for a description of the method of unblinding a participant during the 
study , should such action be warranted . 
  04ZGY9 
  05PZF8

PRODUCT: V114 46
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
7 DISCONTINUATION OF S TUD Y INTERVENTION AND P ARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study  intervention does not represent withdrawal from the study .
As certain data on clinical events bey ond study  intervention discontinuation may  be 
importan t to the study , they  must be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -speci fied vaccination 
regimen will still continue to participate in the study  as specified in Section 1.3, unless the 
consent is withdrawn for the participant (Section 7.2). A participant may  discontinue from 
study  intervention (including receipt of V114, Prevn ar13™ and concomitant vaccines 
provided in the study ) but continue to participate in protocol -specified ,AE-monitoring 
activities (see Section 8.12.3 for details) .
Participants may  discontinue study  intervention at any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  the 
investigator or the Sponsor if study intervention is inappropriate , the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1.12 .
A participant must be discontinued from study inter vention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant’s legally  acceptable representative requests to discontinue study  
intervention.
•The participant’s treatment assignment isunblinded by  the investigator, MSD subsidiary , 
or through the emergency unblinding call center.
•The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, place sthe participant at unnecessary  risk from continued 
administratio n of study  intervention.
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent” .Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention . 
  04ZGY9 
  05PZF8

PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant’s legally  acceptable 
represent ative withdraws consent from the stud y.
If a participant withdraws from the study, they will no longer receive stud y treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.12. The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
7.3 Lost to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed :
•The site must attempt to contact the participant’s legally  acceptable representative and 
reschedule the missed visit. I f the participant’s legally  acceptable representative is 
contacted, the participant’s legally  acceptable representative should be couns eled on the 
importance of maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the 
participant’s legall y acceptable representative at each missed visit (eg, telephone calls 
and/or a certified letter to the participant’s legally  acceptable representative last known 
mailing address or locally equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines.
8 STUD Y ASSESSMENTS AND PR OCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for en suring that procedures are conducted by  
appropriatel y qualified or trained staff. Delegation of study site personnel responsibilities 
will be docu mented in the Investigator Trial File Binder (or equivalent). 
  04ZGY9 
  05PZF8

PRODUCT: V114 48
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
•All study -related medica l decisions must be made by an investigator who is a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all partici pants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may  be utilized for screeni ng or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons relate d to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent , be obtained from the participant’s legall y 
acceptable re presentative . In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
Approximate ly5 mL of blood will be drawn at each of Visit s4, 5, and 6 for immunogenicit y 
assay s.The maximum amount of blood collected from each participant over the duration of 
the study will not exceed 15mL.
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent , from each potential participant’s legall y acceptable 
representative prior to participating in a clinical study or future biomedical r esearch. If there 
are changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically  qualified designee must ensure the appropriate 
consent is in place.
8.1.1.1 General Informed Consent
Consent must be documented onthe consent form by the dated signature of the participant’s 
legally  acceptable representative along with the dated signature of the person conducting the 
consent discussion. 
  04ZGY9 
  05PZF8

PRODUCT: V114 49
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
A cop y of the signed and dated consent form should be given to the participant’s legall y 
acceptable representative before the individual’s participation in the study .
The initial informed consent form , any subsequent revised written informed consent form , 
and an y written information provided to the partici pant’s legall y acceptable representative 
must receive the Institutional Review Board/Independent Ethics Committee’s ( IRB/IEC’s )
approval/favorable opinion in advance of use. The participant ’slegally  acceptable 
representative should be informed in a timely manner if new information becomes available 
that may  be relevant to the willingness for the participant to continue participation in the 
study . The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the dated signature of
the participant’s legally  acceptable representative .
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed cons ent wil l adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements.
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  quali fied designee will explain the future biomedical r esearch 
consent to the participant’s legally  acceptable representative , answer all of his/her questions, 
and obtain written informed consent before performin g any procedure related to the future 
biomedical research sub study . A cop y of the informed consent will be gi ven to the 
participant’s legall y acceptable representative .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a qualified 
physician ,to ensure that the participant qualifies for the study .The investigator should 
consult with the Sponsor’s Clinical Director for any  questions about participant eligibility .
If the participant meets any  of the Exclusion Criteria with an asterisk (*), Visit 1 may  be 
rescheduled for a time when these criteria ar e not met.
8.1.3 Participant Identification Ca rd
The legall y acceptable representative for each participant will be given a participant 
identification card identifying the individual as a participant in a research study . The card 
will contain study  site contact information (including direct telephone numbers) to be used in 
the event of an emergency. The investigator or qualified designee will provide the legally  
acceptable representative for each participant with a participant identification card 
immediately afte r written informed consent is provided . At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card. 
  04ZGY9 
  05PZF8

PRODUCT: V114 50
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
The participant identification card also contains contact in formation for the emergency  
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  the inve stigator or qualified designee before 
vaccination at Visit 1.Note: Birth weight (kg) and g estational age will be documented in the 
participant’s medical history .
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medications taken b y the participant within 30 days before the first dose of study vaccine at 
Visit 1.The receipt of hepatitis B vaccine at birth needs to be reviewed and documented in 
the participant ’s chart.
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the stud y.
If a medical condition requires the use of steroids, immunoglobulin, blood, or blood products 
during a subje ct's participation in this study , one of the individuals listed on the SPONSOR 
Contact I nformation page must be notified as soon as possible . Any  concurrent medication or 
medical treatment must be recorded on the appropriate eCRF. 
It is important to recor d any  analgesic or antipy retic use that occurs on the day  of vaccination 
on the eVRC and appropriate eCRF. Concomitan t medications taken after Visit 1 and non -
study  vaccines received since Visit 1 will be recorded with the eVRC as specified in 
Section 8.3.3.
Licensed pediatric vaccines listed in Table 3will be recorded on the appropriate eCRF. To 
avoid an y confounding results, concomitant injectable vaccines should no t be administered in 
the same limb as V114 or Prevnar 13™. Documentation of which limb was used for the 
administration of V114 or Prevnar 13™ must be recorded on the eVRC (Section 8.3.3) and 
appropriate eCRF. Documentation of injection -site location for the concomitant injectable 
vaccines must be recorded on the appropriate eCRF.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization .Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants. 
  04ZGY9 
  05PZF8

PRODUCT: V114 51
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Any participant who is screened multiple times will retain the or iginal screening number 
assigned at the initial screening visit. Specific details on the screening visit requirements are 
provided in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and admi nister the study  vaccine. Procedures for handling, preparing, and administering the 
unblinded vaccines are provided in the Investigator Trial File Binder. Unblinded study  
personnel should not have contact with participants for an y stud y-related 
procedures/ assessments after administration of study  vaccines, which includ es all safet y 
follow -up procedures.
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
If the V114 is provided as a sy ringe : Prior to administration of study  vaccine, the unblinded 
pharmacist should shake vigorousl y to obtain a homogenous white suspension. If white -
colored insoluble particle appears, the unblinded pharmacist should use rapid, horizontal 
hand shaking for 5 to 10 seconds while holding the sy ringe in be tween the thumb and index 
finger until complete resuspension. This action should be repeated, as necessary . If 
appearance is otherwise, the vaccine should not be administered. 
If V114 is provided as a vial : Prior to administration of study vaccine, the unblinded 
pharmacist should use rapid, horizontal hand -shaking for up to 5 seconds while holdin g the 
vial in between the thumb and index finger to obtain a homogenous white suspension. This 
action should be repeated, as necessary .If appearance is otherwise, the vaccine should not be 
administered. 
The vaccine should not be used if the vaccine cann ot be resuspended.
All safet y and immunogenicity assessments will be conducted b y blinded personnel, and the 
participant or participant’s parent/guardian will be blinded to the study vaccine received b y 
the participant. Vaccination information, such as Com ponent I dentification Number and time 
of vaccination, must be recorded on the appropriate eCRF as per the Data Entry Guidelines. 
  04ZGY9 
  05PZF8

PRODUCT: V114 52
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
A 0.5 -mL intramuscular dose of study  vaccine will be administered to healthy infants at 
approximately  2, 4, 6, and 12 to 15 mon ths of age. Prevnar 13™ will be supplied as a pre -
filled sy ringe.
The vaccines should be administered at a 90° angle in the anterolateral thigh muscle using 
the provided s yringes with the following needle length and gauge specifications: 1 inch 
needl e, 22 to 25 gauge for infants (2 to 6 months) and 1 to 1¼ inch needle, 22 to 25 gauge for 
toddlers (12 to 15 months). Needles provided in Prevnar 13™ blister packages may  also be 
used.
The study  vaccines are to be administered at the locations recommended in Table 4.If an 
abnormality  (ie, rash) is observed at the site where the previous dose of the study vaccine 
was administered, it is permissible to use the anterolateral m uscle of the other limb to 
administer the following dose of the stud y vaccine.
Unblinded s tudy personnel should follow the preparation and administration instructions for 
Prevnar 13™ as specified in the product label .
8.1.8.1 Timing of Dose Administration
V114 or Prevnar 13™ will be administe red as indicated in Section 1.3. Other pediatric 
vaccines will be administered concomitantly  on the same day  as study  vaccine according to 
the recommended schedule (Se ction 6.5). All p articipants will be observed for 30 minutes
following each vaccination for an y immediate reactions. This observation must be performed 
by blinded site personnel for V114 and Prevnar 13™ (Section 1.3 and Section 6.3.3 ).
Participants must be afebrile for at least 72 hours prior to vaccination. 
Blood samples must be collected before stud y vaccination ,when applicable.
8.1.9 Electronic Vaccination Report Card
The eVRC was developed to be administered electronically  via a hand -held device. This item 
was structured as recommended in the final Food and Drug Adm inistration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant’s legall y acceptable representative in the use of the eVRC as 
indic ated in Section 1.3.
Body temperatures, injection -site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or non-study  vaccinations will be recorded on the 
eVRC as described in Section 1.3 and Section 8.3.3. The investigator or delegate will review 
the data captured on the eVRC with the participant’s legally  acceptable representative as 
indicated in Section 1.3.
For the AEs outlined above, the investigator will use the information provided by the 
participant’s legall y acceptable representative both on the eVRC, and verbally  at the time of 
eVRC review, to appl y the appropriate assessment of intensity  as described in Appendix 3. 
  04ZGY9 
  05PZF8

PRODUCT: V114 53
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.1.10 Telephone Contact Guide for Day 15 Post Each Dose
Site personnel will contact study  participants on Day  15 post each dose to review eVRC data 
with the participant’s legally  acceptable representative. The Day  15 Postdose Telephone 
Contact Guide will be provided by  the Sponsor. This guide is designed to ass ist site 
personnel to collect an y updates or edits to data previously  entered on the eVRC from the 
participant’s legall y acceptable representative . Any  differences between eVRC data and the 
clinical database must be clearl y explained in the participant’s s ource documentation with an 
indication of where the information was obtained (eg, from the Day  15 Postdose Telephone 
Contact with the participant’s legall y acceptable representative ).
8.1.11 Telephone Contact Questionnaire
Site personnel will contact study  partic ipants approximately  6 months after the last dose of 
study  vaccine to collect additional information based on a Telephone Contact Questionnaire 
provided b y the Sponsor. Data to be reported from this discussion will include SAEs and/or 
any updates to previo usly reported safet y information.
8.1.12 Discontinuation and Withdrawal
Participants who discontinue study  intervention prior to completion of the protocol -specified 
vaccination sshould be encouraged to continue to be followed for all remaining stud y visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 6) should be performed (at the time of withdrawal). 
Any AEs that are present at the time of withdrawal should be followed in acco rdance with 
the safet y requirements outlined in Section 8.4 .
8.1.12.1 Withdrawal From Future Biomedical Resear ch
Consent for future biomedical research may  be withdrawn b y the participant’s legally 
acceptable representative. Consent may  be withdrawn b y the legall y acceptable 
representative at any time by contacting the principal investigator for the main study .If 
medical records for the main study  are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently ,the participant's consent for future biomedical r esearch will be with drawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant ’s legally  acceptable representative
of completion of withdrawal. An y anal yses in progress at the time of request for withdrawal 
or alread y performed prior to the request being received b y the Sponsor will continue to be 
used as part of the overall research stud y data and results. No new analys es would be 
generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longe r be a link between  
  04ZGY9 
  05PZF8

PRODUCT: V114 54
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed . 
8.1.13 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONL Y IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a partici pant and /orthe dosage 
administered , he/she will contact the emergency  unblinding call center by t elephone and 
make a request for emergency  unblinding. As requested by  the investigator or medicall y 
qualified designee, the emergency  unblinding call center w ill provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request unblinding of a participant’s treatment assignment, the 
investigator who is a qualified phy sician shou ld make reasonable attempts to enter the 
intensity  of the AEs observed, the relation to study  intervention, the reason thereof , etc., in 
the medical chart. If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the appropriate follow -up medical care can be 
provided to the participant .
Participants whose trea tment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or nonstudy  treating ph ysician must be discontinued from study  
intervention, but should continue to be monitored in the study.
Additionally , the investigator or medically  qualified des ignee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unbl inding in the event that this is required for 
participant safety .
8.1.14 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and /ormaintained to ensure that the data obtained is reliable and/or reproducible.  
  04ZGY9 
  05PZF8

PRODUCT: V114 55
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Documentation of equipment calibratio n must be retained as source documentation at the 
study  site.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure (1)vaccine -induced anti-PnPs s eroty pe-
specific IgG for all the 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F) contained in V114 using the pneumococcal electrochemiluminescence (PnECL )
v2.0 assay , (2) anti-HBsAg concentration using the hepatitis B ECiassay , and (3) anti -
rotavirus IgA using the EIA .
Blood collection, storage and shipment ins tructions for serum samples will be provided in the 
operations/laboratory  manual.
8.2.1 Pneumococcal Electrochemiluminescence ( PnECL )
The Sponsor has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the 15 PnPs seroty pescontained in V114. 
The PnECL  v2.0 assay  is based on the Meso -Scale Discovery  technology , which employ s 
disposable multi -spot microtiter plates. The benefits of the ECL  multiplex technology  over 
the prior enzyme-linked immunosorbent assay methodology  include speed, equivalent or 
better sensitivity , increased dy namic range, the ability  to multiplex, and reductio n in required 
serum sample and reagent volumes. The measurement of immune responses to the 15 
seroty pes included in V114 is performed using an assay  format consisting of 2groups of 7 
and 8 serot ypes each. The PnECL  v2.0 assay  for all 15 seroty pes has unde rgone validation. 
The validation study  evaluated various performance parameters of the assay including 
precision, ruggedness, relative accuracy , dilutional linearity , selectivity , and specificit y. The 
validation results were evaluated against pre -specified acceptance criteria for each of the 
parameters.
The WHO Expert Committee on Biological Standardization has recommended that in -house 
assay s used in immunogenicity  studies designed to evaluate protection against I PD be 
bridged to the WHO reference assay  inorder to maintain the link between immune responses 
to vaccination and the clinical demonstration of protective efficacy against IPD conferred b y 
the 7 conjugated pol ysaccharides in Prevnar™. In 2012 and 2014, the Sponsor formall y 
bridged the original PnE CL assay  to the WHO IgG enzy me-linked immunosorbent assay
(ELISA) in order to determine the PnECL  threshold values that correspond to 0.35 µg/mL  in 
the WHO ELISA for each of the 7 Prevnar™ seroty pes (4, 6B, 9V, 14, 18C, 19F, and 23F) 
and for each of the ad ditional 6 serot ypes (1, 3, 5, 6A, 7F, and 19A) in Prevnar 13™.
A confirmatory  study  was performed to formall y bridge the optimized PnECL  assay  (v2.0) to 
the WHO reference ELISA, and to assess the PnECL  threshold values that correspond to 
0.35 µg/mL  measur ed using the WHO ELISA for each of the serot ypes in V114, including 
the Prevnar 13™ serotypes and serotypes 22F and 33F, which were not previously  assessed. 
The bridging of the optimized PnECL  to the WHO ELI SA is complete, and the data showed 
good concorda nce between the PnECL  and WHO ELISA around the 0.35 μg/mL threshold  
  04ZGY9 
  05PZF8

PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
value for all 15 serot ypes. It is recommended that a single PnECL threshold value of 0.35 
µg/mL  be applied to each of the 15serot ypes.
8.2.2 Hepatitis B Enhanced Chemiluminescence (ECi) Assay
The purpose of the hepatitis B ECi assay  is to detect total antibody  to human plasma -derived 
HBsAg subt ypes ad and ay before and after vaccination with HBsAg containing vaccine(s). 
This is the primary  assay used to evaluate the serological response to the v accine(s). The 
assay  is a solid phase sandwich enzy me-labeled immunoassay . Results for the assay  are 
reported in mIU/mL.
This assay  involves the reaction of anti -HBs in a test sample with HBsAg (ad and ay  
subty pes) coated onto the wells. A horseradish peroxidase (HRP) -labeled HBsAg conjugate 
(ad and ay  subt ypes) then formed a complex with the bound anti -HBs, forming an “antigen 
sandwich”. Unbound mate rials were removed b y washing. A reagent that contained 
luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent 
was added to the wells. The HRP in the bound conjugate catal yzed the oxidation of the 
lumin ol derivative, producing light. The electron transfer agent increased the level and 
duration of the lig ht produced. The amount of HRP conjugate bound and subsequent light 
produced was indicative of the concentration of anti -HBs present in the sample.
Three internally  prepared control serum pools, consisting of a high -positive, low -positive, 
and negative con trol, were used to monitor the performance of the assay . These pools were 
each prepared from 4 individual human immune sera obt ained from an external vendor. 
Additionally , there were anti -HBs positive and negative manufacturer -supplied controls, 
which were prepared from freeze -
dried recalcified human plasma. The hepatitis B WHO
International reference standard at 10 mIU/mL was also ru n as a control in every  assay . The 
lower limit of quantification ( LLOQ )of the assay  is 5 mI U/mL.
8.2.3 Rotavirus Serum IgA Enzyme -Linked Immunosorbent Assay (EIA)
The purpose of the Rotavirus serum IgA EIA is to detect IgA antibody to Rotavirus before 
and after vaccination with rotavirus -containing vaccine. This is one of the primary  assay s 
used by  the Laboratory  for Specialized Clin ical Studies, Division of Infectious Diseases of 
Cincinnati Children’s Hospital Medical Center to evaluate the serological response to the 
vaccine. This assay  is used to detect and quantify  anti-rotavirus IgA from serum. Results for 
the assay  are reported as units/mL  anti-rotavirus IgA.
This assay  is run in a standard EIA format. Microtiter plates are coated with a rabbit 
anti-rotavirus IgG antibody . Rotavirus l ysate (positive wells) from the WC3 strain of the 
virus and Mock Infected ly sate (negative wells) from the MA104 cell line are added to the 
coated microtiter plates. After incubation and washing, standards, controls, and serum 
dilutions are added. The negative wells allow for measurement of rotavirus specific response 
by correcting each sample, contro l, and standard curve serum optical density (OD) for 
non-specific antibody  binding. IgA antibody  detection occurs by  first adding a biotiny lated 
anti-human IgA to the wells, followed by  an avidin -biotin -peroxidase complex and substrate.  
  04ZGY9 
  05PZF8

PRODUCT: V114 57
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
The quantity  of ant i-rotavirus IgA is determined by comparison of the delta OD (DOD) from 
sample wells to the standard curve. The DOD is defined as the average of the positive well 
ODs minus the average of the negative well ODs. All serum samples are run in duplicate at 
2dilutions. A cut -off of ≤1.15 units/mL  was deriv ed during the assay  validation.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided below . The total amount of blood to be drawn over the cours e of the study  (from 
prestudy  to poststudy  visits), including approximate blood volumes drawn by  visit and by  
sample ty pe per particip ant, can be found in Section 8 .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinati ons
A complete ph ysical examination will be performed at Visit 1. A targeted phy sical 
examination will be performed at subsequent vaccination visits (Visits 2, 3, and 5). Any 
clinically  significant abnormality  will be re corded on the appropriate eCRF.
The full and targeted physical examination procedures both include obtaining vital signs 
(heart rate, respiratory  rate, and rectal temperature), auscultation of the heart and lung, and 
examination of the abdomen. I n addition, a full phy sical examination will i nclude an 
assessment of the head, eyes, ears, nose and throat (HEENT), skin, l ymph nodes, 
neurological s ystem, and musculoskeletal sy stem.
Findings related to the physical examinations should be documented in the participant’s 
chart/source documentation.
8.3.2 Body Temperature Measurement
Pre-vaccination rectal temperatures will be taken by  study  staff at Visits 1, 2, 3, and 5. 
Participants who have febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary  
temperature ≥37.8°C [≥100.0°F]) occurring at or within 72 hours of Visits 1, 2, 3 and 5 must 
be rescheduled. Rectal is the preferred method of obtaining participant’s temperature. 
Axillary  (underarm) is an acceptable method but temperature needs to be confirmed by  rectal 
measurement if fever is detected . If an axillary  temperature is reported to be ≥37.8°C 
(≥100.0°F), a rectal temperature must be taken . In this case, both axillary  and rectal 
temperatures must be recorded on the eVRC. Temperature readings should be taken at 
approximat ely the same time each day . Use of temporal or t ympanic thermometers to collect 
temperature for this study is prohibited.
The participant’s legally  acceptable representative will be asked to record a rectal 
temperature reading on the eVRC from Day 1 throug h Day  7 following each vaccination. 
Temperature measurement must be recorded in the eVRC if fever is suspected during Day 8 
through Day 14. 
  04ZGY9 
  05PZF8

PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.3.3 Safety Assessment and Use of the eVRC
All participants will be observed for 30 minutes after each vaccination for an y immediate 
reactions. If an y immediate AEs are observed during this period, the time at which the event 
occurred within this timeframe, as well as the event itself, any concomitant medications that 
were administered, and resolution of the event, must be r ecorded on the appropriate eCRF.
Participant’s legall y acceptable representative will use the eVRC (Section 8.1.9) to document 
the following information:
•Rectal temperatures measured Day 1 (day  of vaccination) through Day  7 following each 
vaccination; Day  8 through Day  14 following each vaccination if fever is suspected
•Solicited injection -site AEs ( swelling, redness, pain or tenderness , and hard lump ) Day  1 
through Day  14postvaccination
•Solicited sy stemic AEs ( irritability , drowsiness, appetite lost, and hives or welts ) Day 1 
through Day  14 postvaccination
•Any other unsolicited injection -site or s ystemic AEs Day  1 through Day  14 
postvaccination
•The limb that was used for the ad ministration of V114 or Prevnar 13™ ( Note: the study  
will report injection -site AEs f rom V114 or Prevnar 13™ a nd not from concomitant 
injectable vaccines ; the location of V114 or Prevnar 13™ administration can be used b y
the participant’s legally  acceptable representative to monitor the appropriate limb for 
injection -site AEs related toV114 or Prevnar 1 3™)
•Use of an y analgesic or antipy retic on the day of vaccination
•Concomitant medications and non -study  vaccinations Day  1 to Day  14 postvaccination
8.3.4 Clinical Laboratory Assessments
There are no laboratory  safet y evaluations required by the protocol.
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant's 
legally  acceptable representative). 
  04ZGY9 
  05PZF8

PRODUCT: V114 59
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
The investigator and an y desig nees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for out come according to Section 8.4.3 .
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Perio d and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  the investigator if they cause the 
participant to be excluded from the study , or are the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other re portable safety  events must be reported by  the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through 14 day s postvaccination. SAEs must also be reported throughout the 
duration of the in dividual’s participation in the study , regardless of whether or not related to 
the Sponsor’s product .
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1. A death that occurs prior to the participant completing the study.
OR
2. An SAE that is considered by  an investigator who is a qualified ph ysician to be 
vaccine -related.
Investigators are not obligat ed to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the ev ent to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or design ee within the time frames as indicated in Table 5. 
  04ZGY9 
  05PZF8

PRODUCT: V114 60
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
Specified Follow -
up PeriodReporting Time 
Period:
After the Protocol 
Specified F ollow -up 
PeriodTimeframe 
to Report 
Event and 
Follow -up 
Inform ation 
to 
SPONSOR
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine r elated
-any death until 
participant completion 
of study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureNot applicable since participants are infants .
Event of Clinical 
Interest There are no Events of Clinical Interest for this study. Not 
Applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant ’s legall y 
acceptable representative is the preferred method to inquire about AE occurrence. 
  04ZGY9 
  05PZF8

PRODUCT: V114 61
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investiga tor is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including cancer and overdose will be followed until resolution, stabilization, until the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in 
randomized participants for outcome. Further information on follow -up procedures is given 
inAppendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs wil l be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidelines for 
Good Clinical Practice [GCP] ).
Investigator safety  reports must be prepared for sus pected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific s afety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Information in this section is not ap plicable since participants are infants.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study .
8.4.7 Events of Clinical Interest (ECI s)
There are no events of clinical interest for this study .
8.5 Treatment of Overdose
In this stud y, an overdose is the administration of more than 1 dose of an y individual study  
vaccine in an y 24-hour period . 
  04ZGY9 
  05PZF8

PRODUCT: V114 62
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
No specific information is available on the treatment of overdose.
Decisions regarding dose interruptions or m odifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
All reports of overdose must be reported b y the investigator within 5 calendar day sto the 
Sponsor either by electronic media or paper. Electronic reporting procedures can be found in 
the EDC data entry  guidelines. Paper reporting procedures can be found in the Investigator 
Trial File Binder (or equivalent).
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant ’s legally  acceptable representative signs the future biomedical r esearch 
consent, the following specime ns will be obtained as part of future biomedical r esearch:
•Buccal swab DNA for future research
•Leftover stud y serum at the central laboratory  stored for future research after aliquoting 
samples for completion of immunogenicit y testing
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study .
8.10 Biomarkers
Biomarkers are not evaluated in this study .
8.11 Medical Resource Utilization and Health Economics
Medical Resource U tilization and Health Econom icsare not evaluated in this study .
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8. 
  04ZGY9 
  05PZF8

PRODUCT: V114 63
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
8.12.1 Screening
Screening proced ures will be conducted at Visit 1as outlined in Section 1.3.
8.12.2 Treatment Period/Vaccination Visit s
Requirements during the treatment period are outlined in Section 1.3.
If the participant develops a new clinical condition during the stud y that makes him/her
ineligible for thestudy , the investigator should discuss with the Sponsor Clinical Director as 
soon as possible. The decision to continue the participant on study intervention requires the 
mutual agreement of the investigator, the Sponsor, and the participant’s legally acc eptable 
representative.
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
A participant may  discontinue from study  intervention ( including receipt of V114, 
Prevnar 13™ and concomitant vaccines provided in the study ) but continue to particip ate in 
protocol -specified ,AE-monitoring activities as outlined in Section 1.3, as long as the 
participant’s legally acceptable representative does not withdraw consent. Blood draws for 
immunogenicit y testing could occur if agreed to by the participant’s l egally acceptable 
representative at the discretion of the investigator.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study . If, after the 
study  has begun, but prior to any  unblinding, changes are made to primary  and/or secondary  
hypotheses, or the statistical methods related to those hypotheses, then the protocol will be 
amended (consi stent with I CH Guideline E -9). Changes to exploratory  analy ses made after 
the protocol has been finalized, but prio r to unblinding, will be documented in a 
supplemental SAP (sSAP) and referenced in the Clinical Stu dy Report (CSR) for the stud y. 
Post hoc exploratory  analy ses will be clearl y identified in the CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12. 
  04ZGY9 
  05PZF8

PRODUCT: V114 64
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Study Design Overview A Phase 3, Multicenter, Randomized, Double -blind Study to Evaluate the 
Interchangeability of V114 and Prevnar 13™ w ithRespect to Safety, 
Tolerability, and Immunogenicity in Healthy Infants (PNEU -
DIRECTION)
Intervention Assignment Participants will be randomly assigned in a 1:1 :1:1:1 ratio to a complete 
dosing schedule of V114 or Prevnar 13™ or one of 3mixed dosing 
schedules of Prevnar 13™/ V114 vaccination groups as specified below :
Group 1: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3: Prevnar 13™ →Prevnar 13™ →V114 →V114
Group 4: Prevnar 13™ →V114 →V114 →V114
Group 5: V114 →V114 →V114 →V114
Analysis Populations Immunogenicity : Per -Protocol (PP)
Safety : All Participants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Anti-pneumococcal polysaccharide (PnPs) serotype -specific 
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) 
for the 13 shared serotypes contained in V114 and Prevnar 13™ at 
30 days postdose 4 (PD4)
Safety :
Proportion of participants with solicite d injection -site AEs ( swelling, 
redness /erythema ,tenderness /pain, and hard lump /induration ) from 
Day 1 through Day 14following any vaccination with V114 or 
Prevnar 13™
Proportion of participants with solicited systemic AEs ( irritability, 
drowsiness/ somnolence , appetite lost/decreased appetite , and hives
or welts/urticaria ) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
Proportion of partici pants with vaccine- related SAEs from Day 1 
through completion of study participation
Key Secondary EndpointsProportion of participants with anti -hepatitis B surface antigen 
(HBsAg) concentration ≥10 mIU/mL at 30 days PD3 of V114 or 
Prevnar 13™
Anti-rotavirus Immunoglobulin A (IgA) Geometric Mean Titer 
(GMT) at 30 days PD 3of V114 or Prevnar 13™
Anti-PnPs serotype -specific IgG GMCs and serotype -specific IgG 
response rates (proportion of participants meeting serotype -specific 
IgG threshold value of ≥0.35 μg/mL) at 30 days following Dose 3 for 
the 15 serotypes contained in V11 4 
  04ZGY9 
  05PZF8

PRODUCT: V114 65
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Statistical Methods for Key 
Immunogenicity AnalysesThe primary immunogenicity objective is descriptive without formal 
hypothesis testing. To address the primary immunogenicity objective, the 
serotype -specific IgG GMCs for 13 shared serotypes contained in V114 
and Prevnar 13™ at 30 days PD4 will be compared betw een groups 
through the estimation of serotype -specific IgG GMC ratios for each of 
the 13 shared serotypes . Estimation of the IgGGMCratios and 
computation of the corresponding 95% confidence inte rvals ( CIs) will be 
calculated using analysis of covariance (ANCOVA) modelwith 
vaccin ation group and stratification factor ( hepatitis B vaccination status 
before enrollment = Yes, No ) as covariates. The pairw ise comparisons
include Group 2 vs Group 1; Group 3 vs Group 1 ;and Group 4 vs 
Group 1.
To addr ess the secondary objective regarding the non-inferiority 
evaluation of immunogenicity of RECOMBIVAX HB™ when given 
concomitantly with V114 or Prevnar 13™ , the proportions of participants 
with anti -HBsAg concentration ≥10 mIU/mL at 30 days PD3 of V114 or 
Prevnar 13™ will be compared betw een groups . The betw een-treatment 
difference based on the proportions of participants with anti -HBsAg 
concentration ≥10 mIU/mL [V114 (Group 5) minus Prevnar 13™ (Group
1 +Group 2)] and its 95% CI will be calculated using stratified Miettine n 
and Nurminen (M&N) method [Miettinen, O. and Nurminen, M. 1985] .
To address the secondary objective regarding the non -inferiority 
evaluation of immunogenicity of RotaTeq™ w hen given concomitantly 
with V114 or Prevnar 13™, the anti -rotavirus IgA GMT at 30 days PD3 
of V114 or Prevnar 13™ will be compared betw een groups through the 
estimation of anti-rotavirus IgA GM Tratios . Estimation of the 
anti-rotavirus IgA GMT ratio [V114 (Group 5)/Prevnar 13™ (Group 1 +
Group 2)] and the corresponding 95% CIs will be calculated using
ANCOVA with vaccin ation group and stratification factor (hepatitis B 
vaccination status before enrollment = Yes, No )as covariates.
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) 
will be provided for betw een-vaccin ation group differences in the 
percentage of participants with event s; these analyses will be performed 
using the M&N method [Miettinen, O. and Nurminen, M. 1985] .The 
pairw ise comparisons for Tier 1 and Tier 2 endpoints include Group 2 vs 
Group 1; Group 3 vs Group 1; Group 4 vs Group 1; and Group 5 vs 
Group 1.
Interim Analyses To support the periodic review of safety and tolerability data across the
V114 Phase 3 pediatric program, an external unblinded statistician will 
provide unblinded interim safety summaries to an independent external 
Data Monitoring Committee (DMC )for their review. There are no plans 
to conduct an interim analysis of unblinded immunogenicity data in t his 
study. However, unblinded immunogenicity data will be made available 
to the DMC upon request to enable a benefit -risk assessment .
Multiplicity No multiplicity adjustment will be made for primary objective as there are no 
formal hypothesis tests associated w ith prima ry immunoge nicity /safety in 
this study .
No m ultiplicity adjustments will be made for the two secondary 
objectives/hypotheses for the non -inferiority of V114 and Prevnar 13™ 
when given concomitant use with RECOMBIVAX HB™ and RotaTeq ™. 
Both endpoints will be tested individually at the one -sided 0.025 level.  
  04ZGY9 
  05PZF8

PRODUCT: V114 66
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Sample Size and Power Immunogenicity :
The primary immunogenicity objective for this study is descriptive. The 
study will randomize participants in a 1:1:1:1:1 ratio to the 5 vaccination 
groups. The overall sample size w ill be approximately 900 with 180 
participants into each of the 5 vaccination groups. There isno hypothes is 
to be evaluated for primary objective. Section 9.9.1 provides information
about the expected variability of the IgG GMC ratios given the sample 
size.
For the hypothesis (H1), the study has ~96% pow erat a 1-sided 2.5% 
alpha -level to demonstrate that RECOMBIVAX HB™ adm inistered 
concomitantly with V114 is non -inferior to RECOMBIVAX HB™ 
administered concomitantly with Prevnar 13™ as measured by the 
proportion of participants with anti -HBsAg concentration ≥10 mIU/mL at 
30 days PD3 .
For the hypothesis (H2), the study has ~98% pow er at a 1-sided 2.5% 
alpha -level to demonstrate that RotaTeq™ administered concomitantly 
with V114 is non -inferior to RotaTeq™ administered concomitantly with 
Prevnar 13™ as measured by the anti-rotavirus IgA GMT at 30 days 
PD3. Details are provided in Section 9.9.1.
Safety :
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within and between the vaccination groups.
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor. This study  will be conducted as a double -
blind study  under in -house blinding procedures. The official, final database will not be 
unblinded until medical/scienti fic review has been performed, protocol deviations have been 
identified, and data have been declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  treatment assignment . Randomization will be implemented in an IRT. Blinding issues 
related to the planned interim anal yses are described in Section 9.7 .
9.3 Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stated in Section 3.
9.4 Analysis Endpoints
Immunogenicit y and safety analy sis endpoints that will be evaluated for within - and/or 
between -vaccine differences are listed below.
9.4.1 Immunogenicity Endpoints
A description of immunogenicity  assessmen ts is contained in Section 8.2.Immune responses 
will be measured for the 13 shared seroty pes contained in V114 and Prevnar 13™ (1, 3, 4, 5,  
  04ZGY9 
  05PZF8

PRODUCT: V114 67
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) or all 15 seroty pes contained in V114 (1, 3, 4,
5,6A,6B,7F,9V,14,18C, 19A, 19F, 22F, 23F, and 33F).
The primary  immunogenicity  analy sis endpoint i ncludes:
•Anti-PnPs seroty pe-specific IgG GMCs for the 13 shared seroty pes contained in V114
and Prevnar 13™ at 30 day s PD4
The secondary  immunogenicity  anal ysis endpoints include:
•Proportion of participants with anti -HBsAg concentration ≥10 mI U/mL at 30 day sPD3
of V114 or Prevnar 13™
•Anti-rotavirus IgA GMT at 30 day s PD3 of V114 or Prevnar 13™
•Anti-PnPs seroty pe-specific IgG GMCs for the 15 seroty pes contained in V114 at 30 
days PD3
•Anti-PnPs seroty pe-specific IgG response rates ( proportion of participants w ith IgG 
≥0.35 µg/mL ) for the 15 seroty pescontained in V114 at 30 day s PD3
The exploratory  immunogenicity  anal ysis endpoint sinclude :
•Anti-PnPs seroty pe-specific IgG GMCs for the 15 seroty pescontained in V114 prior to 
Dose 4
•Anti-HBsAg GMCs at 30 day s PD3
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
adverse events and postvaccination temperature measurements following any  vaccina tion 
with V114 or Prevnar 13™.
The safet y analysis endpoints include:
•Proportion of participants with solicited injection -site AEs ( redness /erythema , swelling, 
hard lump /induration , and tenderness /pain)from Day 1 through Day 14following an y 
vaccination with V114 or Prevnar 13™ 
  04ZGY9 
  05PZF8

PRODUCT: V114 68
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
•Proportion of participants with solicited systemic AEs ( irritability , 
drowsiness /somnolence , hives or welts /urticaria , and appetite los s/decreased appetite )
from Day 1 through Day 14following an y vaccination with V114 or Prevnar 13™
•Proportions of participants with the broad AE categories consisting of an y AE, a vaccine -
related AE, a nSAE, an AE which is both vaccine -related and serious, and 
discontinuation d ue to an AE, and the proportion of participants who died
•Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points Day 1 through Day 7 following an y vaccination with 
V114 or Prevnar 13™
9.5 Analysis Populati ons
9.5.1 Immunogenicity Analysis Populations
The PP population will serve as the primary  population for the analy sis of immunogenicit y 
data in this study . The PP population consists of all randomized participants without 
deviations from the protocol that may su bstantially  affect the results of the immunogenicit y 
endpoint(s). Potential deviations that may result in the exclusion of a participant from the PP 
population for all immunogenicity  anal yses include:
Failure to receive primary infant series vaccination (V 114/Prevnar 13™ Doses 1, 2, 
and 3) as per randomization schedule
Receipt of prohibited medication or prohibited vaccine prior to stud y vaccination
Additional potential deviations that may result in the exclusion of a participant from the PP 
population for specific immunogenicit y analyses (depending on the timepoint for anal ysis) 
include:
Failure to receive V114, Prevnar 13™, RECOMBIVAX HB™ , or RotaTeq™
according to vaccination schedule required at the timepoint for the anal ysis
Failure to receive the scheduled doses of V114 or Prevnar 13™ (at least 28 day s 
between Doses 1 and 2 and between Doses 2 and 3 [for PD3 and pre -dose 4 anal ysis], 
12 months to 1 day  prior to 16 months of age for Dose 4 [for PD4 PP analy ses])
Receipt of prohibited medication or p rohibited vaccine pri or to a blood sample 
collection
Collection of blood sample at the timepoint for the anal ysis outside of the 
pre-specified window (as described in Se ction 1.3)
The final determination on protocol deviations, and thereby the composition of the PP 
population, will be made prior to the final unblinding of the database. Participants will be  
  04ZGY9 
  05PZF8

PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
included in the vaccination group to which they are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoint s. The FAS population consists of all randomized 
participants who received all study  vaccination srequired at the timepoint for the analysis and 
have serology  result. Participants will be included in the vaccination group to which they  are 
randomized for the analysis of immunogenicity data using the FAS populat ion.
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in the APaT population, which consists of all randomized 
participants who received at least 1 dose of stud y vaccination. Participants will be included in 
the group corresponding to the study  vaccination they  actuall y received for the anal ysis of 
safet y data using the APaT population. This will be the group to which they are randomized 
except for participants who take incorrect stud y vaccination; such participants will be 
included in the vaccination group corres ponding to the study  vaccination actually  received.
At least 1 temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy sis of temperature.
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in
Section 9.6.1 and Section 9.6.2 , respectivel y. Unless otherwise stated, all statistical tests will 
be conducted at the α=0.05 (2 -sided) level. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicit y objective s.
Primary Endpoint
The primary  endpoint, anti-PnPs seroty pe-specific IgG GMC for 13 shared seroty pes 
contained in V114 and Prevnar 13™ at 30 day s PD4 ,is a descriptive endpoint. The primary  
endpoint will be summarized for each vaccination group. The confidence limits for IgG 
GMCs are the exponentiated confidence limits for the mean natural log concentrations, based 
on 1-sample t -distributions. Additionally , the estimation of seroty pe-specific IgG GMC ratios 
(between -group comparison) for 13 shared serot ypes and its 95% CI will be calculated using 
the ANCOVA model utilizing the log -transformed antibody  response as the response and 
vaccin ation group andstratification factor (hepatitis B vaccination status before enrollment =
Yes, No) as covariate s. The pairwise comparisons for primary  objective include Group 2 vs 
Group 1; Group 3 vs Group 1 ;and Group 4 vs Group 1 . The s ame approach will be use dto  
  04ZGY9 
  05PZF8

PRODUCT: V114 70
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
evaluate the secondary  endpoint ,seroty pe-specific IgG GMC ratios comparing Group 5 vs 
Group 1.
Secondary Endpoints
Secondary Endpoint # 1/Hypothesis (H1)
For the h ypothesis (H1),the proportion of participants with anti -HBsAg concentration ≥10 
mIU/mL at 30 day s PD3 from participants administered primary  infant series dosing 
schedule V114 (Group 5) con comitantly  with RECOMBIVAX HB™ will be compared to 
participants administered a complete primary  infant series dosing schedule of Prevnar 13™ 
(Group 1 + Group 2) concomitantly with RECOMBIVAX HB™ at 30 day s PD3 of V114 or 
Prevnar 13™ via the following non -inferiorit y hypotheses:
H0: p1-p2≤-0.10 versus
H1: p1-p2>-0.10
Where p 1is proportion of participants with anti -HBsAg concentration ≥10 mI U/mL at 30 
days PD3 forGroup 5 and p2is proportion of participants with anti -HBsAg concentration 
≥10 mI U/mL at 30 day s PD3 forGroup 1 + Group 2.
RECOMBIVAX HB™ administered concomitantly with V114 is non -inferior to 
RECOMBIVAX HB™ administered concomitantly with Prevnar 13TMif the lower bound of 
the 2-sided 95% CI for the between -treatment difference between Group 5 vs (Group 1 +
Group 2)>-0.10.The proposed 10 percentage point margin is the same as those observed in 
previous Merck vaccine concomitant use studies evaluating similar antigens . The stratified
Miettinen and Nurminen approach will be used for the anal ysis of this endpoint . The
stratification factor is hepatitis B vaccination status before enrollment (Yes, No )[Miettinen, 
O. and Nurminen, M. 1985] .
Secondary  Endpoint #2/H ypothesis (H2)
For the secondary hypothesis (H2), the anti -rotavirus IgA GMTs between participants 
administered a complete primary  infant series of V114 (Group 5) concomitantly  with 
RotaTeq™ versus participants administered a complete primary  infant series dosing schedule
of Prevnar 13™ (Group 1 +Group 2)concomitantly  with RotaTeq™ at 30 day sPD3 of 
V114 or Prevnar 13™ will be assessed via the following non -inferiorit y hypotheses:
H0: GMT 1/GMT 2≤0.50 versus
H1: GMT 1/GMT 2>0.50
Where GMT 1is the anti-rotavirus IgA GMT for the V114 (Group 5 )andGMT 2is the anti-
rotavirus IgA GMT for the Prevnar 13™ (Group 1 + Group 2). A ratio of 0.50 corresponds to 
a 2.0 -fold decrease of anti-rotavirus IgA GMT in the V114 as compared with the 
Prevnar 13™ . The proposed noninferiorit y margin of 0.50 for anti -rotavirus responses was 
chosen based on what was observed in a previous Merck concomitant use study for this  
  04ZGY9 
  05PZF8

PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
endpoint . The anti-rotavirus IgA responses i n the V114 group (Group 5)are non -inferior to 
the anti -rotavirus IgAresponses in the Prevna r13™ group (Group 1 +Group 2) if the lower 
bound of the 2 -sided 95% CI  on the GMT ratio ( V114/ Prevnar 13™ ) >0.50 .
The within -group anti-rotavirus IgAGMT along with 2-sided 95% CI s will be computed. 
Point estimates of anti-rotavirus IgA GMTs are the exponentiated estimates of the mean 
natural log concentrations. The confidence limits for GMTs are the exponentiated confidence 
limits for the mean natural log concentrations, based on 1 -sample t -distributions. 
Additionally , anti-rotavirus IgA GMT ratios [V114 (Group 5) /Prevnar 13™ (Group 1 +
Group 2)]along with 2-sided 95% CIs will be computed. The 95% CI for the ratio will be 
calculated using the ANCOVA model utilizing the log -transformed antibody  titers as the 
response with vaccination group and stra tification factor (hepatitis B vaccination status 
before enrollment =Yes, No)as covariates .
For the other secondary  endpoints and exploratory continuous descriptive endpoint s ;anti-
PnPs seroty pe-specific IgG GMCs at 30 day s PD3 of V114 or Prevnar 13™ and prior to
Dose 4 and anti-HBsAg GMCs at 30 day s PD3 , each vaccination groups will be evaluated
separately . The point estimates will be calculated by  exponentiating the estimates of the 
mean of the natural log values and the within -group CI s will be derived by exponentiating 
the CI s of the mean of the natural log values based on the 1-sample t-distribution. For the 
dichotomous endpoints that immune responses meet threshold value as defined in the 
objectives , the within -group CI s will be calculated based on the exact method proposed b y 
Clopper and Pearson [Collett, D. 1999] .
Reverse Cumulative D istribution Curvesfor IgG concentrations at 30 day s PD3 and 30 day s 
PD4will be graphicall y display ed by serotype.
A detailed analy sis strategy  for immunogenicity  endpoints is listed in Table 6. 
  04ZGY9 
  05PZF8

PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table 6 Analy sis Strategy  for Immunogenicit y Variables
Endp oint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical Method‡ Analysis 
PopulationMissing 
Data 
Approach
Prim ary Endpoint
Anti-PnPs IgG GMCs for the 13 shared 
serotypes contained in V114 and 
Prevnar 13™ at 30 days PD4P
ANCOVA§
(estimate, 95% CI)PPMissing data 
will not be 
imputedS FAS
Secondary Endpoint #1/Hypothesis (H1)
Proportion of participants with anti-
HBsAg concentration ≥10 m IU/mL at 
30 days PD3 ofV114 or Prevnar 13™PStratified Miettinen 
and Nurminen¶
(estimate, 95% CI , p-
value)PP Missing data 
will not be 
imputed S FAS
Secondary Endpoint #2/Hypothesis (H2)
Anti-rotavirus IgA GMT at 30 days 
PD3 of V114 or Prevnar 13™PANCOVA§
(estimate, 95% CI , p-
value)PPMissing data 
will not be 
imputedS FAS
Other Secondary Endpoints
Anti-PnPs IgG GMC sfor the 15 
serotypes contained in V114 at 30 days 
PD3PDescriptive Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
Proportion of participants with anti-
PnPs IgG ≥ 0.35 µg/mL for the 15 
serotypes contained in V114 at 30 days 
PD3PDescriptive Statistics
(estimate, 95% CIǁ)PPMissing data 
will not be 
imputed
†P = Primary approach; S = Supportive approach.
‡Statistical models are described in further detail below:
§
ANCOVA model with log-transformed antibody responses as response variab leand vaccination group, 
and stratification factor (hepatitis B vaccination status before enrollment = Yes, No) as covariates.
ǁWithin group summaries provided using exact method proposed by Clopper and Pearson .
¶
Stratification factor (hepatitis B vaccination status before enrollment = Yes, No) .
CI= confidence interval ; FAS = Full Analysis Set; GMC = Geom etric Mean Concentration; GMT = Geometric 
Mean Titer; HBsAg = Hepatitis B surface antigen ; IgA = Immunoglobulin A; IgG = Immunoglobulin G; PD = 
postdose; PnPs = pneumococcal polysaccharide ; PP=Per-Protocol
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and postvaccination temperature measurements. The extended safet y follow -up period 
will occur 6 months following the last dose of vaccination. Safet y and tolerability will be  
  04ZGY9 
  05PZF8

PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
assessed during the entire study  period . Primary  safet y evaluation will be t hrough 14 day s 
postvaccination following an y vaccination. Selected safet y summaries will be provided for 
the extended safet y follow -up period through the end of the stud y for each vaccine group .
The anal ysis of safet y results following any vaccination will follow a tiered approach ( Table
7). The tiers differ with respect to the an alyses that will be performed. AEs (specific terms as 
well as sy stem organ class terms) are either pre -specified as “Tier 1” endpoints, or will be 
classified as belonging to "Tier 2" or "Tier 3" based on the number of events observed .The 
pairwise comparisons for Tier 1 and Tier 2 endpoints include Group 2 vs Group 1; Group 3 
vs Group 1; Group 4 vs Group 1; and Group 5 vs Group 1.
Safety  anal yses will b e based on the observed data (ie, with no imputation of missing safety  
data).
Tier 1 Events
Safety  parameters or adverse events of special interest that are identified constitute “Tier 1” 
safet y endpoints that will be subject to inferential testing for sta tistical significance with 
p-values and 95% CIs to be provided for between -group differences in the proportion of 
participants with events; these anal yses will be performed using the unstratified M&N 
method [Mietti nen, O. and Nurminen, M. 1985] , an unconditional, asymptotic method . For 
this protocol, solicited injection -site AEs ( redness /erythema ,swelling, hard lump /induration , 
and tenderness /pain) from Day  1 through Day  14 postvaccination and solicited sy stemic AEs 
(irritability , drowsiness /somnolence ,hives or welts /urticaria , and appetite loss
/decreased 
appetite ) from Day  1 through Day  14 postvaccination are considered Tier 1 events.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (also via the unstratified M&N method ) 
[Miettinen, O. and Nurminen, M. 1985] .
Membership in Tier 2 requires that at least 4 participants in any  vaccin ation group exhibit the 
event. The threshold of at least 4 events was chosen because the 95% CIfor the between -
group difference in percent incidence will always include zero when vaccination groups of 
equal size each have less th an 4 events and thus would add little to the interpretation of 
potentially  meaningful d ifferences. Because man y 95% CIs for Tier 2 events may  be 
provided without adjustment for multiplicity , the CIs should be regarded as a helpful 
descriptive measure to be used in review, not a formal method for assessing the statistical 
significance of the between -group differences in adverse events.
In addition to individual events that occur in 4 or more participants in an y vaccination group, 
the broad AE categories consisting of the proportion of participants with any AE, a vaccine -
related AE, a nSAE, avaccine -related SAE , discontinuation due to an AE, and the proportion 
of participants who died will be considered Tier 2 endpoints .The proportion of participants  
  04ZGY9 
  05PZF8

PRODUCT: V114 74
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
with maximum temperature measurements meeting the Brighton Collaboration cut points 
will also be considered Tier 2 endpoints.
Tier 3 Events
Safety  endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only  point 
estimates by  vaccination grou p are provided for Tier 3 safety  parameters.
Additionally , solicited AEs may be provided following each vaccination by vaccination
group (Groups 1, 2, 3, 4, and 5)inorder to better describe the safet y of a 4 -dose schedule (3 
infant primary  series + 1 toddler dose) of PCV when switching from Prevnar 13™ to V114 at 
Doses 2, 3, or 4 during the immunization schedule . 
  04ZGY9 
  05PZF8

PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table 7 Analy sis Strategy  for Safety  Parameters
Safety 
Tier Safety Endpoint†p-Value95% CI fo r 
Between -
Group 
Com parisonDescriptive
Statistics
Tier 1Injection -siteredness /erythema (Days 1to14) X X X
Injection -site swelling (Days 1to14) X X X
Injection -sitetenderness /pain (Days 1to14) X X X
Injection -site hard lump /induration (Days 1 to 14) X X X
Irritability (Days 1to14) X X X
Drow siness /somnolence (Days 1 to14) X X X
Hives or welts/urticaria (Days 1to14) X X X
Appetite loss /decreased appetite (Days 1to14) X X X
Tier 2Any AE†X X
Any Vaccine -Related AE†X X
Any SAE†X X
Any Vaccine -Related SAE†X X
Discontinuation due to AE†X X
Death†X X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 7) X X
Specific AEs by SOC and PT‡(incidence ≥4 of 
participants in one of the vaccination groups)X X
Tier 3Specific AEs bySOC and PT‡(incidence <4 of 
participants in all of the vaccination groups)X
†These endpoints are broad adverse event categories. For example, descriptive statistics for the safety 
endpoint of “Any AE” will provide the number and percentage of par ticipants with at least one AE.
‡Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tie r2 endpoints.
AE=adverse event; CI = confidence interval; PT=preferred term; SAE =serious adverse event; 
SOC = system organ class; X = results will be provided
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed by the use of summary tables. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized and the prim ary reasons for screening failure and discontinuation 
will be display ed. Demographic variables (eg, age, race, and gender ,birth weight [kg],
gestational age ), baseline characteristics, prior and concomitant vaccinations and therapies 
will be summarized by vaccination group either by  descriptive statistics or categorical tables. 
  04ZGY9 
  05PZF8

PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
9.7 Interim Analyses
A periodic review of safety  and tolerability  data across the V114 Phase 3 pediatric program 
will be conducted b y an independent, unblinded, external DMC. A description of the 
structure, function, and guidelines for decision -making by  the DMC, along with the timing 
and content of the safet y reviews will be outlined in the DMC charter. Information regarding 
the composition of the DMC is provided in Appendix 1. There ar e no plans to conduct an 
interim analy sis of unblinded immunogenicity data in this study . However, unblinded 
immunogenicit y data will be made available to the DMC upon request to enable a benefit -
risk assessment.
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblin ding will be restricted to an external unblinded statistician performing 
the interim anal ysis.
The DMC will serve as the primary  reviewer of the results of the safet y interim anal yses and 
will make recommendations for discontinuation of the study or protoc ol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this Executive Oversight Committee (EOC) of the Sponsor (and 
potentially  other limited SPONSOR personnel) may  be unblinded to results at the 
intervention level in order to act on these recommendations. The extent to which individuals 
are unblinded with respect to results of interi m analy ses will be documented by  the external 
unblinded statistician. Additional logistical details will be provided in the DMC Charter.
Intervention -level results from the safety  interim analy sis will be provided by  the external 
unblinded statistician to the DMC. Prior to final study unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
interim analy ses.
9.8 Multiplicity
There will be no multiplicity  adjustment for the primary  immunogenicit y objective as there is 
no formal h ypothesis testing. No multiplicity  adjustments will be made for both secondary  
objectives /hypotheses for the non -inferio rity of immunogenicit y of V114 and Prevnar 13™ 
when given concomitant use with RECOMBIVAX HB™ and RotaTeq ™. Both endpoints 
hypotheses will be tested individually  at the one -sided 0.025 level. No multiplicity  
adjustments will be made for the safet y comparis ons. For assessment of safety  endpoints, 
application of a multiplicity  adjustment could potentially  mask a safet y concern. Thus, no 
control of T ype I error rate beyond the per -comparison 1 -sided α = 0.025 level will be 
applied to the safet y analyses, with the realization that spurious statistica l significance may  
be observed. 
  04ZGY9 
  05PZF8

PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
Theprimary  immunogenicity  objective for this study  is descriptive . The study  will 
randomize partic ipant sin a 1:1 :1:1:1 ratio to the 5 vaccination group s. The over all sample 
size will be approximately 900with 180participants into each of the 5 vaccination group s. It 
is assumed that approximately 135participants per vaccination group will be evaluable for 
PP immunogenicity  analy ses at 30 day s PD 4(based on a 7 5% evaluability  rate).
For the descriptive primary  endpoint IgG GMC, t he width of the 95% CIs for the serot ype-
specific IgGGMCratios depend o n the sample size, variability  of the natural log 
concentrations, and the magnitude of the IgG GMCratio. The 95% CIs for various 
hypothetical IgG GMCratios at 30 day s PD4 and standard deviation (SD) estimates for the 
natural log titers are displayed in Table 8.
Table 8 95% CI s for Vary ing Hypothetical IgG GMC Ratios and Vary ing Standard 
Deviations with 135 Evaluable Participants in Each Vaccination Group
Standard 
Deviation of 
Natural Log 
Titers†Serotype -specific IgG GMC Ratios†
0.5 0.8 1 1.2 1.5
0.5 (0.44, 0.56 ) (0.71, 0.9)  (0.89, 1.13) (1.06, 1.35) (1.33, 1.69)
1 (0.39, 0.64) (0.63, 1.02) (0.79, 1.27) (0.94, 1.52) (1.18, 1.91)
1.5 (0.35, 0.72) (0.56, 1.15) (0.70, 1.43) (0.84, 1.72 ) (1.05, 2.15)
2 (0.31, 0.81) (0.50, 1.29) (0.62, 1.61) (0.74, 1.94) (0.93, 2.42)
†The estimates of the standard deviation and IgG GMC ratio are representative of those observed in a 
previous MSD study .
CI = confidence interval; GMC = Geometric Mean Concentration; IgG = Immunoglobulin G
For the secondary endpoints, t he power is ~96% and ~98% for each of the 2non-inferiority
hypotheses when RECOMBIVAX HB™ orRotaTeq™ administered concomitantly with 
V114 or Prevnar 13 ™,respectively .
For the secondary endpoint #1/hypothesis (H1) , the study has ~96% power at a 1-sided 
2.5% alpha -level to demonstrate RECOMBIVAX HB™administered concomitantly  with 
V114 is non -inferior to RECOMBIVAX HB™ administered concomitantly with 
Prevnar 13™as measured by the proportion of participants with anti -HBsAg concentration 
≥10 mI U/mL 30 day s PD3 based on the following assumptions: (1) an approximately  80% 
evaluability  rate at PD3 as observed in V114 -008pediatric study ; (2) anon-inferiorit y 
margin of -0.10for the difference (Group 5 – [Group 1 +Group 2]);and (3)an underl ying 
response rate (proportion of partici pants with anti -HBsAg concentration ≥10 mI U/mL 
30days PD3 of V114 or Prevnar 13™ )of 95% for Prevnar 13™ group as observed in a 
previous MSD study . 
  04ZGY9 
  05PZF8

PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
For the secondary endpoint #2/hypothesis (H2) , the study has ~98% power at a 1-sided 
2.5% alpha -level to demonstrate RotaTeq™ admini stered concomitantl y with V114 is non -
inferior to RotaTeq™ administered concomitantly with Prevnar 13™as measured bythe 
anti-rotavirus IgA GMT at 30 day s PD3 based on the following assumptions: (1) an 
approximately  80% evaluability  rate at PD3 as observed in V114 -008pediatric study ; (2) a 
non-inferiorit y margin of 2-fold; (3) SD of anti -rotavirus IgA responses in log scale is 1.7 as 
those observed in previous Merck study, and (4 ) the true GMT ratio (Group 5/[Group 1 +
Group 2])for anti-rotavirus IgAresponses is 1.0.
9.9.2 Sample Size and Power for Safety Analyses
The probability  of observing at least 1SAE in this study  depends on the number of 
participants vaccinated and the underl ying incidence of participants with a nSAE in the study  
population. Calculations below assume that 100% of the randomized participants will be 
evaluable for safet y analyses. There is an 80% chance of observing at least one SAE among 
180participants in each of the complete and mixed dosing regimens of V114 and 
Prevnar 13™if the underly ing incidence of a nSAE is 0.89 % (1 of every  112participants 
receiving the vaccine). There is a 50% chance of observing at least one SAE among 180
participants in the complete and mixed dosing regimens of V114 and Prevnar 13™ group if 
the underl ying incidence of a nSAE is 0.38% (1 of every  260participants receiving the 
vaccine). If no SAE s are observed among 180participants, this study  will provide 97.5% 
confidence that the underly ing percentage of participants with a nSAE is <2.03% (one in 
every  49 p articipants).
Table 9summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability  for a variety  of hypothetical underly ing incidences of
an adverse ev ent. These calculations assume 180participants in each group and are based on 
a 2-sided 5% alpha level. The calculations are based on an as ymptotic method proposed by  
Farrington and Manning (1990) [Farrington, C. P. 1990] ; no multiplicity  adjustments were 
made. 
  04ZGY9 
  05PZF8

PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Table 9 Differences in Incidence of Adverse Event Rates between the 2Vaccination 
Group sThat Can be Detected With an ~80% Probability  (Assuming 2-sided 5% alpha l evel 
with 180Participants in each Group)
Incidence of Adverse Event Risk Difference
Complete and mixed dosing 
schedule s of V114 (%)
N=180Prevnar 13™ (%)
N=180Percentage Points
4.5 0.1 4.4
8.6 2 6.6
13.5 5 8.5
20.6 10 10.6
27 15 12
33 20 13
44.2 30 14.2
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group.
Based on an asymptotic method proposed by Farri ngton and Manning (1990 )[Farrington, C. P. 1990]
9.10 Subgroup Analyses
Subgroup anal yses (eg, hepatitis B vaccination status before enrollment = (Yes, No ), race,
sex (male, f emale ) will be performed for the primary  immunogenicity  endpoint and selected 
safet y endpoints (summary of AEs and summary of solicited AEs). Details of subgroup 
analyses will be provided in the sSAP .
9.11 Compliance (Medication Adherence)
The number and proportion of randomized participants receiving each vaccination will be 
summarized (Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  the number and proportion of randomized 
participants administered V114 or Prevnar 13™ and the number an d proportion of 
randomized participants administered RECOMBIV AX HB™ and RotaT eq™  at each 
vaccination schedule . 
  04ZGY9 
  05PZF8

PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the pa rty (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply t o investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (i e, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on m edical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to s uccessfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, comp leteness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  04ZGY9 
  05PZF8

PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results o f its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the re commendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contri bution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publi cations.
III.Participant Protection
A. Ethics Committee Review (Institutiona lReview Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidential ity, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challengi ng, additional payments may be 
made to compensate for the time spent in extra recruiting efforts. 
  04ZGY9 
  05PZF8

PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible p articipants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics comm ittee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Ot her Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations , Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sp onsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the part icipant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the particip ant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities . 
  04ZGY9 
  05PZF8

PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the inve stigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representati ve), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  signing the consent form, the participant agrees 
to this process. If stud y documents will be photocopied during the p rocess of verify ing 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency  review upon request b y those agencies.
10.1.4 Committees Structure
10.1.4.1 Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
10.1.4.2 Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor Senior 
Manageme nt. The EOC will receive and decide upon any  recommendations made by  the
external DMC regarding the study . 
  04ZGY9 
  05PZF8

PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.1.4.3 External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim dat a from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, consider the overall ri sk and benefit to study  participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter tha t is 
reviewed and approved by all the DMC members.
10.1.5 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standar d editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity  is not directed by  the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined b y mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements.
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) o f 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials .gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial direc tive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations an d study  site contact information. 
  04ZGY9 
  05PZF8

PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees not to submit an y information about this study  or its results to those 
registries. 
10.1.7 Compliance with Law, Audit, and Debarmen t
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use G CP: Consolidated Guideline and other generally  
accepted standards of good clinical practice); an d all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations spo nsored b y MSD, is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the s tudy 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  author ity. 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically  signing the CR F.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y. 
  04ZGY9 
  05PZF8

PRODUCT: V114 86
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit s tudy-related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall b e made available at the study  site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested by the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of partici pants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit yof the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. T he 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s I RB/IEC. 
  04ZGY9 
  05PZF8

PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.2 Appendix 2: Clinical Laboratory Tests
Not applicable 
  04ZGY9 
  05PZF8

PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical st udy participant, temporally  
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provided b y, or distributed by the Sponsor for human use in this study.
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinicall y significant in the 
medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diag nosed after study  intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overd ose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associate d clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer. 
  04ZGY9 
  05PZF8

PRODUCT: V114 89
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Events NOT meeting the AE d efinition
•Medical or surgical p rocedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.7 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpati ent hospitalization or prolongation of existing hospitalization
•Hospitalization is defined as an inpatient admission, regardless of length of stay, even if 
the hospitalization is a precautionary measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is diagnosed 
prior to the use of an MSD product and is documented in the participant’s medical 
history .
d.Results in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct normal 
life functions.
•This definition is not intended to include experiences of relativel y minor medical 
signifi cance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) that may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis. 
  04ZGY9 
  05PZF8

PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize the 
participant or may  require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the above definition. These e vents should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to t he Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics rep orts) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in l ieu of completion of the AE CRF page.
•There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the cop ies of the medical records before submission to the 
Sponsor.
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE. 
  04ZGY9 
  05PZF8

PRODUCT: V114 91
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Assessment of i ntensity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interf ering with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something i s wrong).
-Severe: An event that prevents normal everyday  activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for
pediatric studies, extremely distressed or unable to do usual activities).
•Injection site redness ,swelling , or hard lump from the day  of vaccination through Day 14
postvaccination will be evaluated b y maximum size.
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that suppor ts the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors ? 
  04ZGY9 
  05PZF8

PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
-Rechallenge: Was the par ticipant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ’S PRODUCT, OR I F RE -EXPOSU RE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
- Y es, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more lik ely explained by  the Sponsor ’s product than by  another cause.
-No, there is not a reasonable possibility  of Sponsor ’s product relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor ’s product is not reasonable OR the AE 
is more likely  explained by  another cause than the Sponsor’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very im portant 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment. 
  04ZGY9 
  05PZF8

PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE , SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) too l.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use the 
paper AE Reporting form.
•Reference Section 8.4.1  for reporting tim e requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next sect ion).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent). 
  04ZGY9 
  05PZF8

PRODUCT: V114 94
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the prefe rred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent). 
  04ZGY9 
  05PZF8

PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not applicable 
  04ZGY9 
  05PZF8

PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.5 Appendix 5: Collection and Management of Specimens for Future Biomedical 
Rese arch
1.Definitions
Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body  responds to a treatment for a dise ase or condition . 
Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on dru g/vaccine response.2
DNA: Deox yribonucleic acid.
RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
•The biology  ofhow drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
•Other pathway s drugs/vaccines may  interact with
•The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor.
3.Summary of Procedures for Future Biomedical Resear ch.
Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy
Informed Consent 
  04ZGY9 
  05PZF8

PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained duri ng 
screening for protocol enrollment from all participants or legal guardians, at a study visit 
by the investigator or his or her d esign ee. Informed consent for future biomedical 
research should be presented to the participants on the visit designated in t he SoA. If 
delay ed, present consent at next possible Participant Visit. Consent forms signed b y the 
participant will be kept at the clinical study site under secure storage for regulatory 
reasons.
A template of each study site’s approved informed consent w ill be stored in the Sponsor’s 
clinical document repository .
eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be captured in 
the eCRFs . Any specimens for which such an info rmed consent cannot be verified will be 
destroy ed.
Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined in 
the SoA. I n general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from s pecimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sp onsor, or an additional third party  (eg, a university  investigator) designated by 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch  
  04ZGY9 
  05PZF8

PRODUCT: V114 98
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contacting the principal investigator for the main study. If medical 
records for the main study  are still available, the investigator will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main s tudy use only . If specimens were collected from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/o r destruction, if applicable. It is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal in formation and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 years from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adeq uatel y addressed.
Specimens from the study  site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponso r-designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures ,and this destr uction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is  
  04ZGY9 
  05PZF8

PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Partic ipants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant or the participant’s legall y acceptable representative inclu de: Lack of 
relevance to participant health, limitations of predictive capability, and concerns 
regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make resu lts accessible on a public website in order to 
rapidly  report this information to doctors and participants. Participants will not be 
identified by  name in any published reports about this study  or in any  other scientific 
publication or presentation.
10.Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomed ical research should be e mailed directly  to 
clinical.specimen.management@merck.com.
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2.International Conference on Harmon isation [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -
genomic -data-and-sample- cod.html 
3.Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, Scope 
and Public Health Benefits of Exploratory  Biomarker Research: A Guide for I RBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/  
  04ZGY9 
  05PZF8

PRODUCT: V114 100
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
4.Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informa tional Brochure for I RBs/IECs and Investigational Site Staff. Available at http://i -
pwg.org/ 
  04ZGY9 
  05PZF8

PRODUCT: V114 101
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.6 Appendix 6: Country -specific Requirements
Not applicable 
  04ZGY9 
  05PZF8

PRODUCT: V114 102
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
10.7 Appendix 7: Abbreviations
Abbreviation Expanded Term
ACIP Advisory  Committee on Immunization Practices
Admin administration
AE adverse event 
ANCOVA analysis of covariance
APaT All Participants as Treated
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CSR Clinical Study  Report
DMC Data Monitoring Committee
DNA deox yribonucleic acid 
ECi enhanced chemiluminescence
ECL electrochemiluminescence
eCRF electronic case report form
EDC electronic data collection 
EIAor ELISA enzy me-linked immunosorbent assay
EMA European Medicines Agency
EOC Executive Oversight Committee
eVRC Electronic Vaccination Report Card
FAS Full Anal ysis Set
FDAAA Food and Drug Administration Amendments Act
GCP Good Clinical Practice 
GMC Geometric Mean Concentration
GMT Geometric Mean Titer
HBsAg hepatitis B surface antigen
HEENT head, ey es, ears, nose and throat
HIV human immunodeficiency virus
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IgA Immunoglobulin A
IgG Immunoglobulin G
IM intramuscular
IMP investigational medicinal product
IPD invasive pneumococcal disease
IRB Institutional Review Board 
IRT interactive response technology
M&N Miettinen and Nurminen
MSD Merck Sharp & Dohme Corp. 
  04ZGY9 
  05PZF8

PRODUCT: V114 103
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
Abbreviation Expanded Term
NIMP non-investigational medicinal product
NSAE non-serious adverse event
PCV pneumococcal conjugate vaccine
PD postdose
PnECL pneumococcal electrochemiluminescence
PnPs Pneumococcal pol ysaccharide
PP Per-Protocol
PT preferred term
PY person -years
RNA ribonucleic acid
SAC Scientific Advisory  Committee
SAE serious adverse event
SD Standard deviation
SoA schedule of activities
SOC system organ class
SUSAR suspected unexpected serious adverse reaction
TC telephone contact
US United States
WHO World Health Organization 
  04ZGY9 
  05PZF8

PRODUCT: V114 104
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
11 REFERENCES
[Centers for Disease Control 
and Prevention 2008]Centers for Disease Control and Prevention 
(CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine 
introduction -eight states,1998 -2005. MMWR 
Morb Mortal Wkly  Rep. 2008 Feb 
15;57(6):144 -8.04KW8S
[Ciapponi, A., et al 2016] Ciapponi A, L ee A, Bardach A, Glujovsky D, 
Rey-Ares L, Luisa Cafferata M, et al. 
Interchangeability between pneumococcal 
conjugate vaccines: a s ystematic review and 
meta -analysis. Value Health Reg Issues. 
2016;11C:24 -34.04XCFT
[Collett, D. 1999] Collett D. Statistical inference for binary  data. 
In: Collett D, ed. Modelling Binary Data. 
New York: Chapman & Hall, 1999:17 -42.03NVVC
[Drijkoningen, J. J 2014] Drijkonin gen JJ, Rohde GG. Pneumococcal 
infection in adults: burden of disease. Clin 
Microbiol I nfect. 2014 May ;20 Suppl 5:45 -
51.04NFHN
[Farrell, D. J, et al 2007] Farrell DJ, Klugman KP, Pichichero M. 
Increased antimicrobial resistance among 
nonvaccine serot ypes of Streptococcus 
pneumoniae in the pediatric population after 
the introduction of 7 -valent pneumococcal 
vaccine in the United States. Pediatr Infect 
Dis J. 2007 Feb;26(2):123 -8.04KWD9
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics 
and Sample Size Formulae for Comparative 
Binomial Trials with Null Hy pothesis of Non -
Zero Risk Difference or Non -Unity  Relative 
Risk. Stat Med Vol. 9,1447 -1454 (1990)04FS6L 
  04ZGY9 
  05PZF8

PRODUCT: V114 105
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
[Guevara, M., et al 2016] Guevara M, Barricarte A, Torroba L, Herranz 
M, Gil -Setas A, Gil F, et al. Direct, indirect 
and total effects of 13 -valent pneumococcal 
conjugate vaccination on invasive 
pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and case -control 
study . Euro Surveill. 2016;21(14).04KSQ3
[Hicks, L . A., et al 2007] Hicks LA, Harrison LH, Flannery B, Hadler 
JL, Schaffner W, Craig AS, et al. Incidence of 
Pneumococcal Disease Due to Non -
Pneumococcal Conjugate Vaccine (PCV7) 
Seroty pes in the United States during the Era 
of Widespread PCV7 Vaccination, 199 8-
2004. J I nfect Dis 2007;196:1346 -54.03QT0G
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu 
AA, Virtanen MJ, Nohy nek H, et al. Impact 
of ten -valent pneumococcal conjugate 
vaccination on invasive pneumococcal 
disease in Finnish childre n a population -
based study . PLoS One. 2015 Mar 
17;10(3):e0120290.04KW7F
[Lepoutre, A., et al 2015] Lepoutre A, Varon E, Georges S, Dorleans F, 
Janoir C, Gutmann L , et al. I mpact of the 
pneumococcal conjugate vaccines on invasive 
pneumococcal disease in F rance, 2001 -2012. 
Vaccine. 2015 Jan 3;33(2):359 -66.04KW88
[Lexau, C. A., et al 2005] Lexau CA, Ly nfield R, Danila R, Pilishvili T, 
Facklam R, Farley  MM, et al. Changing 
epidemiology  of invasive pneumococcal 
disease among older adults in the era of 
pediat ric pneumococcal conjugate vaccine. 
JAMA 2005;294(16):2043 -51.03RBPW
[Liu, G. F., et al 2017] Liu GF, Hille D, Kaplan SS, Goveia MG. 
Postdose 3 G1 serum neutralizing antibody  as 
correlate of protection for pentavalent 
rotavirus vaccine. Hum Vaccin Immuno ther. 
2017;13(10):2357 -63.04XNC5 
  04ZGY9 
  05PZF8

PRODUCT: V114 106
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
[Martinelli, D., et al 2014] Martinelli D, Pedalino B, Cappelli MG, 
Caputi G, Sallustio A, Fortunato F, et al 
Towards the 13- valent pneumococcal 
conjugate universal vaccination: effectiveness 
in the transition era between PCV7 and 
PCV13 in I taly, 2010 -2013. Hum Vaccin 
Immunother. 2014;10(1):33 -9.04KW8B
[Metlay , J. P., et al 2006] Metlay  JP, Fishman NO, Joffe M, Edelstein 
PH. I mpact of pediatric vaccination with 
pneumococcal conjugate vaccine on the risk 
of bacteremic pne umococcal pneumonia in 
adults. Vaccine 2006;24:468 -75.03RC46
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
Analy sis of Two Rates. Stat Med 1985;4:213 -
26.03QCDT
[Moore, M. R., et al 2015] Moore MR, L ink-Gelles R, Schaffner W , 
Lynfield R, Lexau C, Bennett NM, et al. 
Effect of use of 13 -valent pneumococcal 
conjugate vaccine in children on invasive 
pneumococcal disease in children and adults 
in the USA: analy sis of multisite, population -
based surveillance. Lancet I nfect Dis. 201 5 
Feb 3. [Epub ahead of print].043MRP
[Palmu, A. A., et al 2015] Palmu AA, Kilpi TM, Rinta -Kokko H, 
Nohy nek H, Toropainen M, Nuorti JP, et al. 
Pneumococcal conjugate vaccine and 
clinically  suspected invasive pneumococcal 
disease. Pediatrics. 2015 Jul;136 (1):e22 -7.04KVRL
[Pilishvili, Tamara, et al 2010] Pilishvili T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease 
in the era of conjugate vaccine. J I nfect Dis 
2010;201(1):32 -41.03R5S4 
  04ZGY9 
  05PZF8

PRODUCT: V114 107
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
[Ruckinger, S., et al 2009] Ruckinger S, van der Linden M, Reinert RR, 
von Kries R, Burckhardt F, Siedler A. 
Reduction in the incidence of invasive 
pneumococcal disease after general 
vaccination with 7 -valent pneumococcal 
conjugate vaccine in Germany . Vacc ine 
2009;27:4136 -41.03QYQQ
[Schillie, S. F. 2013] Schillie SF, Murphy  TV. Seroprotection after 
recombinant hepatitis B vaccination among 
newborn infants: a review. Vaccine. 
2013;31:2506 -16.04XNBY
[Truck, J., et al 2016] Truck J, Jawad S, Goldblatt D, R oalfe L, 
Snape MD, Vo ysey M, et al. The antibod y 
response following a booster with either a 10 -
or 13- valent pneumococcal conjugate vaccine 
in toddlers primed with a 13 -valent 
pneumococcal conjugate vaccine in earl y 
infancy . Pediatr Infect Dis J. 2016 
Jul;35(7):787 -93.04XDBS
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry  
patient -reported outcome measures: use in 
medical product development to support 
labeling claims [I nternet]. Washingt on: U.S. 
Department of Health and Human Services; 
2009. Available from: 
https://www.fda.gov/downloads/drugs/guidan
ces/ucm193282.pdf04MG9J
[Van Damme, P. 2016] Van Damme P. Long -term protection after 
hepatitis B vaccine. J I nfect Dis. 2016 Jul 
1;214:1 -3.04X00F
[Velázquez, F. R., et al 2000] Velázquez FR, Matson DO, Guerrero ML, 
Shults J, Calva JJ, Morrow AL, et al. Serum 
antibody  as a marker of protection against 
natural rotavirus infection and disease. J 
Infect Dis 2000;182:1602 -9.03Q3KY 
  04ZGY9 
  05PZF8

PRODUCT: V114 108
PROTOCOL/AMENDMENT N O.:027-00
V114 -027-00 FINAL   PROTOCOL 25-JUL-2018
[Wagenvoort, G. H., et al 
2016]Wagenvoort GH, Knol MJ, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  
MH, et al.  Risk and outcomes of invasive 
pneumococcal disease in adults with 
underly ing conditions in the post -PCV7 era, 
The Netherlands. Vaccine. 2016 Jan 
12;34(3):334 -40.04KTDB
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, L adhani SN, 
Sheppard CL, Slack MP, Miller E. Effect of 
the 13 -valent pneumococcal conjugate 
vaccine on invasive pneumococcal disease in 
England and Wales 4 y ears after its 
introduct ion: an observational cohort study . 
Lancet Infect Dis. 2015 May ;15(5):535 -43.04KTF2
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, 
Imohl M, von Kries R. Impact of 10 -  and 13-
valent pneumococcal conjugate vaccines on 
incidence of invas ive pneumococcal disease 
in children aged under 16 y ears in German y, 
2009 to 2012. Euro Surveill. 2015 Mar 
12;20(10):21057.04KTFC
[Whitney , Cynthia G., et al 
2003]Whitney  CG, Farley  MM, Hadler J, Harrison 
LH, Bennett NM, Ly nfield R, et al. Decline in 
invasive pneumococcal disease after the 
introduction of protein -polysaccharide 
conjugate vaccine. N Engl J Med 
2003;348(18):1737 -46.03QT0D 
  04ZGY9 
  05PZF8
